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Abstract 
 Bacteria utilize complex enzymatic machinery to create diverse secondary 
metabolites.  The architectural complexities of these small molecules are enhanced by 
nature’s ability to synthesize non-proteinogenic amino acids for incorporation into these 
scaffolds.  Many of these natural products are utilized as therapeutic agents, and it would 
be advantageous to understand how the bacteria create various non-natural amino acid 
building blocks.  With a greater understanding of these systems, engineering could be 
used to create libraries of potentially useful natural product analogs.  
 The tyrosine aminomutase SgTAM from the soil bacteria Streptomyces 
globisporus catalyzes the formation of -tyrosine in the biosynthestic pathway of the 
antitumor enediyne C-1027.  SgTAM is homologous to the histidine ammonia lyase 
family of enzymes whose activity is dependent on the methylideneimidazole-5-one 
(MIO) prosthetic group.  Unlike the lyase enzymes, SgTAM catalyses additional 
chemical transformations resulting in an overall 2,3 amino shift in the substrate L-
 x 
tyrosine to generate (S)--tyrosine.  The precise mechanistic role of MIO in this novel 
family of aminomutases has not been established.  We report the first X-ray crystal 
structure of an MIO based aminomutase and confirm the structural homology of SgTAM 
to ammonia lyases.  Further work with mechanistic inhibitors provide structural evidence 
of the mechanism by which MIO dependent enzymes operate.  
 We have also investigated LnmQ, an adenylation domain in the biosynthetic 
pathway of leinamycin.  Leinamycin is an antitumor antibiotic that was isolated from soil 
samples in 1989.  LnmQ is responsible for the specific recognition of D-alanine and 
subsequent activation as an aminoacyl adenylate species.  We have cloned the gene into a 
DNA vector and expressed it in E. coli.  Upon purification of the protein, crystallization 
conditions have been tested.  Synthesis of an inhibitor that mimics the aminoacyl 
adenylate product catalyzed by LnmQ has been completed.  Crystallization with this 
inhibitor will provide better quality crystals and a catalytically informative co-complex.    
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Chapter 1: 
 
 
A Review of Cofactor 
Independent Electrophilic Catalysis 
 
 2 
1.1 Introduction  
The study of enzymes and the reactions they catalyze has been an active field of 
research since the mid-19
th
 century.
1
 Originally, enzyme activity was thought to be a 
‘living’ process that was inherent in the cellular cultures being investigated; it was not 
until the work of Buchner regarding the fermentation of sugars, that proteins, not whole 
cells, were shown to be responsible for this activity.   
This work began a period of research focused more on the structure and nature of 
these enzyme catalysts than the catalyzed reaction.  Much work was done using the 
relatively new technique of X-ray crystallography to obtain a ‘snap-shot’ of the enzyme 
on a molecular level.  The first X-ray structure of a complete protein was not obtained 
until 1960 when the structure of hemoglobin was solved by Perutz.
2
 Myoglobin had been 
solved in 1958, but was not completely modeled until 1961. 
Having X-ray crystallography as a tool at the enzymologist’s disposal would 
cause many new questions to arise.  Enzymologists were no longer satisfied with only 
knowing the starting materials and products associated with the enzymatic 
transformations.  The question of how these macro-catalysts were facilitating the 
reactions being observed was now becoming an increasingly important question.  The 
field of mechanistic enzymology evolved, using the tools of the enzymologist and the 
organic chemist.  The study of mechanistic organic chemistry was being applied to the 
transformations being observed in these biological systems.  
Like all fields in the physical sciences, the continual advance of technology has 
benefited the field of mechanistic enzymology a great deal.  To be able to structurally 
 3 
characterize molecules on the range of kilo-daltons at the molecular level has allowed for 
a clear understanding of many reaction processes.  However, it is not always clear what is 
occurring in reaction pathways, and often times, conclusions drawn from structural data 
alone can be misleading.  Mistakes in the literature will go unchallenged for years until a 
new technique or the application of other techniques is able to shed light on the problem.
3
   
One problem that has drawn a great deal of interest over the years is enzyme 
mediated electrophilic catalysis.  Proteins are made up of amino acids that contain acid, 
basic, and nucleophilic residues; however there are no naturally occurring electrophilic 
groups available in the 
functional repertoire of proteins.  
Enzymes are known to catalyze 
such reactions by employing 
electrophilic cofactors instead of 
amino acids.  Utilization of a 
cofactor allows the enzyme to enhance its reactivity by borrowing reactivity from a small 
molecule bound in or around the active site.  Flavin-dependent oxidation enzymes are an 
example of this type of enzymatic family.
4
  
A different class of electrophilic enzymes, that have been under investigation 
since the 1950’s, are the non-oxidative ammonia lyase and aminomutase enzymes. In 
1952, Hayashi and White initially showed that urocanic acid was liberated from the 
degradation of L-histidine in cell free extracts of Pseudomonas fluorescens.
5
 Early work 
suggested that there were no external cofactors present.  In 1969, Wickner made the 
Figure 1. The structures of urocanic acid and 
dehydroalanine. 
 4 
assumption that dehydroalanine was present in the active site of this histidine ammonia 
lyase (HAL) reaction (Figure 1).
6
 Years of investigation into this new class of 
electrophilic enzyme showed that it was present in all three kingdoms of life, and was 
responsible for a wider range of reactivities than simply catabolism.  Not until a crystal 
structure was solved of HAL from Pseudomonas putida in 1999 did it become clear that 
the active site contained the novel electrophilic moiety, 4-methylideneimidazole-5-one 
(MIO).
3
  
 This chapter will review recent advances in the field of MIO catalysis and provide 
a historical context for the presented work (Figure 2). 
  
1.2 History of MIO 
 In 1926, Edlbacher first reported studies on the catabolism of histidine in liver 
extracts.
7
 Speculation about the mechanism of histidine degradation and the entity 
 
Figure 2. The autocatalytic formation of MIO and a representative reaction of both lyase and the 
subsequent mutase activity. 
 5 
responsible for this transformation resulted in multiple mechanistic proposals.  Later, 
Tabor et al. showed that histidine catabolism by Pseudomonas fluorescens resulted in the 
formation of glutamic and formic acids with the release of ammonia.
5
 Through 
radiolabeling experiments it was determined that something in the cell free extract could 
convert the -amino group of histidine directly to ammonia.  These first experiments led 
to over 50 years of investigation into the mechanism of histidine ammonia lyase (HAL).  
 In 1969, Wickner was able to isolate and purify Pseudomonas HAL and suggest 
that electrophilic catalysis was mostly likely achieved by an active site dehydroalanine 
(2-aminoacrylic acid).
6
 Dehydroalanine would be achieved by the dehydration of an 
active site L-serine or L-cysteine side chain.  Inactivation of HAL by sodium borotritide 
showed, upon protein degradation, the labeling of an active site alanine residue.  This 
method was also used by Hansen and Havir to prove that phenylalanine ammonia lyase 
(PAL) from potato tubers also contained an active site dehydroalanine.
8
 Dehydroalanine 
had been shown to be present in other natural sources isolated at the time, but its role in 
catalysis had not previously been suggested.
9, 10
  
 In 1962, Peterkofsky proposed a mechanism for HAL, involving -amine 
addition into the electrophilic group via conjugate addition.
11
 This mechanism was 
generally accepted and supported for the next 35 years.  Subsequent experimentation 
revealed that product release occurred in two stages, with the unsaturated product leaving 
prior to ammonia.
12
 The structural requirements of the substrate were determined from 
inhibition studies.  These studies revealed that PAL was rather promiscuous in its 
 6 
substrate scope, while HAL displayed more stringent binding requirements for the amino 
acid histidine.
13, 14
   
 In 1985, Hermes et al. showed through extensive labeling studies with different 
substrates that the PAL reaction followed an E1-cB mechanism upon activation of the -
amine of phenylalanine.
15
 This pathway accounted for all mechanistic data obtained to 
date.  Studies suggested that the deprotonation of the -HSi of the substrate phenylalanine 
resulted in the build-up of negative charge in the active site (Figure 3).  Additional 
support for this mechanism (apart from the labeling studies) came from the fact that the 
 
Figure 3. The mechanism of PAL put forth by Hermes et al. in 1985 based on their extensive 
nitrogen and deuterium isoptic labeling studies. 
 7 
reaction had a high optimal pH.  Hermes and coworkers revealed that the initiation of the 
reaction was favored by the deprotonated amine of the substrate interacting directly with 
the electrophilic cofactor.  This basic pH, would also favor a carbanion intermediate.  
 In 1999, the solution of the first aromatic amino acid ammonia lyase crystal 
structure proved that the active site residue was not a dehydroalanine, but the novel MIO 
prosthetic group.
3
 Spectroscopic evidence had previously supported the existence of this 
prosthetic group,
16
 as it possessed a specific absorption pattern in its native form, as well 
as a change in absorption upon nucleophilic addition into the exocyclic alkene.  
Experimental data from previous labeling studies were re-examined with the knowledge 
of the MIO being responsible for activity instead of dehydroalanine.  One of the first 
conclusions to be drawn from the new moiety was that it had increased electrophilic 
character due to its N-3 position lying out of plane of the five-membered ring (Figure 2).  
Many of the conclusions made when dehydroalanine was believed to be the active 
species are still valid, as both MIO and dehydroalanine are non-aromatic electrophilic 
species. 
 
1.3 Ammonia Lyases 
 The initial crystal structure of HAL was solved by Schwede et al.
3
 resulting in 
renewed interest into the mechanism of this class of electrophilic enzymes.  With the 
solution of the overall structure came the elucidation of the active site electrophilic MIO 
cofactor (Figure 4). 
 8 
 The molecular architecture of the HAL superfamily represented a novel protein 
fold.
17
 In the tetrameric structure each monomer is in a head-to-tail relationship with its 
two neighbors.  The active site is at the juncture of the monomer subunits, containing 
amino acid residues from 3 of the 4 monomers in the tetramer (Figure 5).  These enzymes 
crystallize as primarily -helical structures and contain only a few short -strands.  
Packing forces were shown to drive the autocatalytic formation of the active site MIO
18
 
and fully functioning HAL and PAL could be obtained directly from E. coli expression 
systems.  
 A debate concerning the E1-cB mechanism began due to a lingering question of 
how an enzymatic base would be able to deprotonate the non-acidic benzyllic protons of 
aryl amino acids with pKa’s above 40.  Focusing on the enhanced electrophilicity of 
MIO,
3
  Retey speculated that the mechanism could proceed by electrophilic activation of 
the aromatic ring of histidine.
19
 The resulting carbocation would acidify the relatively 
non-acidic -hydrogens, thus facilitating deprotonation by an enzymatic base.  
 
Figure 4. The X-ray structure of HAL from P. putida in 1999 revealed the novel prosthetic group, 
MIO. 
 9 
Tautomerization of the acyl-enzyme intermediate would then result in the elimination of 
ammonia and subsequent regeneration of the active site MIO would liberate uroconate 
(Figure 6). 
 Biochemical studies focusing on secondary kinetic isotopic effects of these 
systems had been done in the past under the assumption that the mechanism would 
proceed with amine activation by the ‘dehydroalanine’. 
15
 Retey et al. reasoned that these 
results were compatible with their suggested mechanism and further labeling studies on 
the aromatic ring showed isotopic effects consistent with the ring being directly involved 
in the reaction pathway.
20
  
 The labeling studies of the aromatic ring done by Retey and coworkers raised 
questions about the validity of the mechanism originally proposed by Peterkofsky.
11
 
Figure 5. A view of the crystal structure of HAL solved from P. putida. The monomer and the 
biologically relevant tetramer are shown. 
 10
Thus, more experiments were performed to probe the mechanism with substrate 
analogues.  In these studies PAL proved more useful as it displays broader substrate 
tolerance, though HAL was able to accept some substitutions to the ring.
19
  
 Retey et al. used assays with HAL and PAL enzymes to support their proposed 
Friedel-Crafts mechanism.
19, 21
 In the case of HAL, previous studies had shown that 
mutants where the active site serine was replaced with either an alanine or threonine, 
were no longer active.
22
   Next, they tested whether 5-nitrohistidine would act as a 
substrate.  Once it was determined that 5-nitrohistidine was an active substrate for HAL, 
they subjected it to reactions with the inactive mutants of HAL. These constructs also 
showed the ability to convert 5-nitrohistidine to its uroconate analog.  Retey and 
coworkers suggested that the nitro group was serving the same purpose as the 
 
Figure 6. The mechanism proposed by Retey and coworkers for HAL activity. The electrophilic 
addition could help explain how an enzymatic base could deprotonate the non-acidic benzyllic 
protons.  
 11
electrophilic cofactor.  Hence, the strong electron withdrawing nature of the nitro group 
acidified the -protons so they could be deprotonated by an enzymatic base.  It was 
unclear whether this data supported one mechanism over the other, as these substrates 
were so different electronically and sterically from the natural substrate.   
 Retey et al. also performed similar experiments with PAL (Figure 7),
21
 where 
they found that inactive mutants of PAL could act upon para-nitrophenylalanine as well 
as meta-hydroxyl-phenylalanine.  This work supported the arguments that electrophilic 
activation of the aromatic ring for the PAL enzymes facilitates deprotonation of the -
hydrogens.  However, this argument also relied on substrates that were electronically 
vastly different than phenylalanine.  In addition, tyrosine was demonstrated to be a poor 
substrate for PAL leading the authors to suggest that the para-hydroxyl group is poorly 
 
Figure 7. The Friedel-Crafts type of mechanism shown by Retey to explain how the PAL family of 
enzymes could deprotonate the benzyllic position of phenylalanine.  
 12
suited for the lyase reaction.  The position of the hydroxyl group in tyrosine does not 
favor a resonance structure that would facilitate the deprotonation of the -hydrogen.  
Retey concluded that no tyrosine ammonia lyases would be found to exist in nature.  This 
assertion would be proven false in the coming years.
23
   
 In 1999, Galpin and coworkers were interested in early reports that showed L-
cysteine and molecular oxygen could cause irreversible inactivation of MIO dependent 
 
Figure 8. In 1999 Galpin et al. postulated this as a plausible mechanism for Cys inactivation of MIO 
in the presence of molecular oxygen.  
 13
enzymes at basic pH.
24, 25
 They treated HAL from P. putida with 50 mM L-cysteine and 
oxygen at a pH of 10.5 for 2 hours, quenched the reactions and performed proteolytic 
digest of HAL.  Fragments were then analyzed by mass and NMR spectrometry.  The 
isolated peptidic fragment that contained the MIO had a covalently bound Cys residue.  
Some of the Cys that was bound to the MIO appeared to be further modified by disulfide 
formation with -mercaptoethanol, which was used during the workup.  By observing -
mercaptoethanol in the active site, it proved that L-cysteine was bound to the MIO by its 
amino group and had its thiol free for disulfide formation.  Despite the amine adduct 
being observed, Galpin favored the Friedel-Crafts mechanism of MIO enzymes, and 
proposed the mechanism shown in (Figure 8).  Galpin argued that the thiolate group 
being in a similar position as the aromatic group of L-histidine was the main reason that 
this reaction was favored over simple addition of the amine into the MIO and subsequent 
oxidation.  
 To build additional support for the Friedel-Crafts mechanism, Retey and 
coworkers refuted the conclusions drawn by earlier mechanistic work
15
 which showed 
that 3,6-dihydrophenylalanine (3,6-DHP) was a substrate for PAL.  In 1985, Hermes et 
al. showed that by reacting 3,6-DHP with PAL, the production of the ,-unsaturated 
acid was achieved, albeit at a slow rate.  This work provided direct evidence that PAL 
could tolerate non-aromatic side chains.  The mechanism proposed by Hermes and co-
workers in 1985 postulates that the reason 3,6-DHP is a substrate, was that it reacted with 
MIO in the same manner as phenylalanine; as an amine adduct.  Retey et al. refuted these 
claims and said that the MIO would react with 3,6-DHP by electrophilic activation of the 
 14
ring.
21
 This reaction would require the MIO to react with a cis-alkene to produce the 
carbocation intermediate as shown (Figure 9A). 
 Due to PAL’s relaxed substrate specificity it was seen as a chemoenzymatic tool 
for the production of enantiomerically pure L-arylalanines.
14
 Gloge and coworkers were 
able to use PAL to convert halogenated cinnamates to their corresponding arylalanines 
(Figure 9B).  PAL was amenable to alterations of its substrate and therefore, the amount 
of reactions accomplished by this system was much greater than those for HAL.  Based 
on its sequence alignment with HAL, it was known that the PAL family of enzymes also 
contained an MIO moiety in its active site.
26
 By running the lyase reactions in a saturated 
aqueous ammonium solution, at a pH of 10, and at 37 
o
C for 12 hours with the ,-
unsaturated acids present in high concentrations, the reverse reaction could be observed.  
 Over the years, several studies have been done to investigate the kinetic isotope 
effects for PAL.
13, 27
 Retey et al. showed that a completely deuterated aromatic ring of 
phenylalanine showed a secondary kinetic isotope effect slightly above unity.  Later 
studies showed this to be incorrect based on ortho-tritiated analogues of phenylalanine.
27
 
According to Lewandowicz, the secondary isotope effects witnessed by Retey et al. was a 
combined isotopic effect from all five position on the aromatic ring, and the calculations 
that they used did not account for all the electronic differences of the system.  A 
secondary isotope effect of a deuterium at the ortho-position of the phenylalanine ring 
should elicit an effect slightly below unity due to the transition from sp
2
 to sp
3
 
hybridization of the carbon atom.
27
 Even though Lewandowicz supported the Friedel-
Crafts mechanism, he stated that the data from isotopic labeling on the aromatic rings of 
 15
L-phenylalanine and L-histidine had largely been misinterpreted and could not support 
one mechanism over the other.
27
 To decipher the actual mechanism, more sophisticated 
experiments needed to be devised.  
 
1.4 Structural Investigations of PAL 
 As discussed, previous structural work and the elucidation of the MIO group was 
done on HAL.  The first crystal structure of PAL from Rhodosporidium toruloides was 
solved in 2004 by Calabrese et al.
28
 This work revealed that PAL and HAL displayed 
 
Figure 9. (A.) The proposed activation of 3,6-DHP by the MIO cofactor as proposed by Retey et al. 
(B.) In 2000 Gloge et al. showed the utility of PAL, by forcing it to do the reverse reaction, creating a 
sampling of L-arylalanines. 
 16
significant structural homology, and showed that the active site of PAL contained a fully 
formed MIO.  The one major difference between the two structures was the presence of 
an extra ~200 residues at the N and C-termini of the polypeptide chain of PAL, which 
resulted in a ‘fan’ region in the overall structure (Figure 10).  The function of this extra 
domain was not believed to be mechanistically relevant.  
 The major revelation that came about with the structural studies of PAL, was that 
it consisted primarily of -helices whose positive helix dipoles pointed at the active site 
(Figure 11).
28
 The presence of an active site surrounded by positive helix dipoles was 
shown to be the case in the HAL structures as well,
3
 but had not been discussed in earlier 
literature.  Mechanistically these positive helix dipoles would strongly disfavor the MIO 
bound carbocation required by the Friedel-Crafts type of mechanism (Figure 7).  
Alternatively, these electrostatic interactions would stabilize a carbanion intermediate 
such as that present in the Hermes E1-cB mechanism (Figure 3).  This structural 
characteristic provides further support for conclusions arising from the deuterium, and 
nitrogen kinetic isotopic effects measured previously.
15
  
 17
 The proposed mechanisms are diametrically opposed in terms of favoring a 
negatively charged intermediate, favoring the original mechanism put forth by 
Peterkofsky (Figure 3).
11
 Retey had proposed the Friedel-Crafts type mechanism to 
account for the ability of an enzymatic base to deprotonate the benzylic position of the 
aryl amino acids.  The enzyme has to overcome a pKa difference of around 30 pH units 
in order to deprotonate the benzylic hydrogen.  Calabrese et al. showed that the 
mechanism of electrophilic addition to the aromatic ring would only account for a change 
of ~4 pH units, leaving 26 units unaccounted for.
28
 In theory, the six positive -helical 
dipoles can perturb the pKa by ~4 to 5 pH units per dipole.  This change would amount to 
an overall lowering effect of ~30 pH units, allowing the enzymatic base to successfully 
deprotonate at the C3 position of the aryl amino acid.
29
 
 
Figure 10. The HAL tetramer on the left and the PAL tetramer on the right. The C and N-terminal 
residues make up the fan regions that cap the PAL tetramer and make it a larger overall structure.  
 18
 Another structural feature realized in this structure was that the pathway to the 
active site was lined with basic residues.
28
 This, along with the ideal pH of the reaction, 
would favor the deprotonated amine of phenylalanine as the species to initiate the lyase 
reaction.  This data also disfavors the electrophilic aromatic substitution put forth by 
Retey, as this pathway requires a protonated amine to serve as an appropriate leaving 
group.
19
   
 Calabrese et al. showed that if the same structural features were present in the 
structure of HAL from P. putida,
3
 then the mechanism must not proceed in a Friedel-
Crafts manner.  It was stated that if the mechanism involved a carbocation, then it would 
be the “sole example of protein architecture working against an enzyme catalyzing its 
own physiological reaction.”
28
 Thus, this work started a new era of re-investigation into 
mechanism, with two schools of thought continually clashing. 
 
Figure 11. Six positive helical dipoles from each member of the lyase family are shown to point at 
the active site MIO. (a) shows PAL, while (b) shows the HAL active site. (figure adapted from 
Calabrese et al. Biochemistry 2004, 43, 11403.) 
 19
 To attempt to answer questions relating to the mechanism of the lyases, 
mutational studies were conducted on the loops that surround the active sites in both 
HAL and PAL enzymes.  None of the structures published at the time had well defined 
active site loops.  It was postulated that these residues were mobile to allow for substrate 
binding and product release.  Of particular interest in these loops was a specific L-
tyrosine residue 110 in PAL from parsley, which is a highly conserved residue between 
all known MIO dependent enzymes.
30
 Pilbak et al. performed modeling studies with the 
loops and concluded that the L-tyrosine of interest must interact directly with the 
substrate.  Pilback showed that upon mutation of this residue to an L-phenylalanine, PAL 
was no longer able to catalyze the reaction.
30
  
 In continued studies of PAL enzymes, it became apparent that some had varying 
abilities to use L-tyrosine as a substrate.  Organisms such as Zea mays (maize) contained 
PAL enzymes that utilized cinnamate as well as p-coumarate as building blocks for 
various secondary metabolites.
31
  Kyndt et al. showed that an enzyme from Rhodobacter 
capsulatus was acting primarily as a tyrosine ammonia lyases (TALs).
23
 They isolated a 
TAL from R. capsulatus that was responsible for generating trans-p-hydroxycinnamic 
acid (4-HCA) directly from L-tyrosine.  4-HCA from R. capsulatus was produced as a 
secondary metabolite to act as the chromophore in a photoactive yellow protein.  This 
was the first time that lyase activity, not from a HAL, was isolated from a bacterial 
source.  Prior to this, PAL activity had been found only in higher plants and some fungi.
23
 
Due to an ever increasing number of known naturally occurring lyases and structural 
information regarding them, various groups began investigating how MIO containing 
 20
enzymes achieved substrate specificity, and if this information could be utilized to predict 
enzymatic function.   
 In 2006 Watts et al. where able to show, through site directed mutagenesis of 
TAL from R. sphaeroides, that substrate selectivity could be switched between L-tyrosine 
and L-phenylalanine.
32
 They used known structures of HAL
3
 and PAL
28
 as a basis to 
generate structural models of their enzymes active site.  A comparison of the structures 
and sequence alignments showed that His89 appeared to be a residue that was highly 
homologous in TALs, whereas PAL enzymes had mostly phenylalanine at this position 
(Figure 12).  By modeling a tyrosine into their active site, they showed that an amine 
adduct with the MIO, would place the phenolic hydroxyl of tyrosine at 2.4 Å from His89.  
Conversely, modeling as a Friedel-Crafts adduct caused the substrate’s phenolic hydroxyl 
 
Figure 12. This is an illustration of the possible activity switch of the tyrosine vs. phenylalanine lyase 
active sites. The TAL is shown in dark colors, while the PAL is shown in lighter colors. His89 in TAL 
favors tyrosine as a substrate, while the phenylalanine sidechain in PAL favors phenylalanine as the 
substrate.  
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group to be 4.3 Å away from this residue.  To further investigate their findings, they 
made the His89Phe mutant of TAL, which displayed selectivity for phenylalanine as a 
substrate over tyrosine.  This work was significant, as it was unprecedented for a single 
mutation to result in a complete change in substrate selectivity between classes of 
enzymes.   
 To prove that this selectivity switch was not an isolated case for the TAL from R. 
sphaeroides, the team next cloned a PAL from Nostoc punctiforme into an E. coli 
expression system.
32
 As expected, this enzyme had a phenylalanine in position 144 which 
aligned with the His89 of TAL.  After making the F144H mutant, substrate tests 
supported that the selectivity had indeed switched towards the function of a tyrosine 
ammonia lyase enzyme.  Not only was this an exciting advance because of its 
implications to engineering of protein selectivity, but it also gave another tool for 
genomic mining of lyases, allowing a better assignment of protein function and 
selectivity.  By showing that this apparent interaction with the phenolic hydroxyl could 
not occur when the substrate was modeled into the active site using a Friedel-Crafts type 
of conformation lends credence to the original mechanism put forth in literature in the 
1960’s.
11, 12
 
 In 2006, Louie et al.
33
 solved the crystal structure of TAL from R. sphaeroides 
which supported Watts’ model of the active site of TAL was correct.
32
 Louie and 
coworkers also solved the crystal structure of the TAL H89F mutant.  In this mutant, the 
ring of phenylalanine occupies the same location as histidine’s imidazole ring in the 
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native structure.  Activity assays revealed that this was indeed a selectivity switch, and 
H89F TAL was now selective for phenylalanine over tyrosine.   
 Attempts were made to crystallize TAL in the presence of tyrosine, or 
phenylalanine in the case of the mutant, but both attempts failed.  Although Louie and 
coworkers were unable to determine the structures bound to substrates, they were able to 
obtain structures of HAL bound to the ,-unsaturated acids coumarate and caffeate.  
Structures were also obtained of the His89Phe mutant in the presence of cinnamate, 
coumarate, and 2-aminoindan-2-
phosphonate (AIP), a PAL 
specific inhibitor (Figure 13).
33
 
These products and other 
analogues were added to the 
protein prior to crystallization.  
There was a high amount of 
ammonium salt in the 
crystallization conditions, and it 
was believed that the MIO was covalently modified by ammonia, disallowing the native 
substrates to bind successfully.  This work provides further evidence for the ordered 
release of products from the active site of lyases shown by Givot and coworkers.
12
 
 These co-crystal structures were the first conclusive evidence to provide support 
for amine activation, as they showed bound intermediates.  The structures of these active 
site complexes were similar to the model put forth by Watts et al.
32
 The alkene of the 
 
Figure 13. Calabrese and coworkers were able to obtain 
crystal structures with both (A.) 4-HCA bound in the active 
site of native TAL and (B.) AIP, a PAL specific inhibitor, 
bound in the active site of the H89F mutant.  
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product analogs are positioned over the MIO, while the interactions with the phenol in 
coumarate and the aromatic ring of cinnamate reacted directly with residue 89 in both 
cases.  Perhaps the most important structural information was obtained from AIP bound 
to the H89F mutant.  In this structure, the amine in AIP appeared to be covalently bound 
to MIO.  Although AIP is only a mimic of phenylalanine, it suggests that the MIO is 
providing direct activation of the substrate amine.  Future studies would have to be done 
with substrate analogs before this conclusion could be unambiguously stated.    
 In the crystal structures of TAL reported by Noel and coworkers, loops appeared 
well organized around the active site, whereas in previous structures of lyases, the 
corresponding loops were unordered.
33
 These loops in TAL were in close proximity to 
the bound analogs and the reactive center of MIO.  Previously, these mobile loops were 
thought to move to interact with the substrate after allowing it to enter the active site, but 
that was speculation based on mutations that abolished enzymatic activity.
30
 Data 
suggested that in the presence of tyrosine, some PALs were able to avoid proteolytic 
degradation, which was attributed to the closing of these mobile loop regions.  The 
observation of these loops in the TAL structure led to the visualization of Tyr60 in the 
active site.  This highly conserved residue appeared to be in perfect position to act as the 
general enzymatic base.  This residue had previously been shown to be important to 
catalysis,
30
 but there was no proof other than mutation of this residue to a phenylalanine 
by Pilbak in PAL, which completely abolished lyase activity.
30
   
 With the new structural evidence brought about by the solution of several PAL 
and TAL enzymes, the mechanistic path was changing course for a second time.  In 1995, 
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when Retey had postulated the Friedel-Crafts mechanism, it had held sway in literature 
even after the publication of the structure of PAL in 2004.
34
 After the publication of TAL 
with products and substrate analogs bound in the enzymatic active site, the original 
mechanism of Peterkofsky had to be reconsidered.
11
 With the realization that helical 
dipoles favored the E1-cB mechanism and that a residue between 9 and 10 Å from the 
MIO’s exocyclic alkene was a selectivity switch in the lyases, the mechanism was most 
likely to occur by amine activation.  
 
1.5 The Significance of -Amino Acids  
 -Amino acids are important molecular building blocks that are an essential part 
of many different organisms.  Although rare in occurrence, examples are found in all 
kingdoms of life (Figure 14).
35-40
 -Amino acids possess the same side chains as their -
amino acid counterparts, allowing them to interact with biological molecules in much the 
same way as naturally occurring primary and secondary metabolites.  -Amino acids also 
share the characteristic of being zwitterionic at physiological pH.  These two 
characteristics combined result in -amino acids having important roles in biological 
systems.  
 25
 One difference between  and -amino acids is that -amino acids are naturally 
occurring primary metabolites that are synthesized into oligomers by template driven 
assembly (ribosomal protein synthesis).  -Amino acids are made as either intermediates 
in primary metabolism
41-43
 or as building blocks for secondary metabolites.
44-46
 In nearly 
 
Figure 14. Several natural products containing -amino acid moieties. 
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all cases, the amino acid is obtained directly from the corresponding -amino acid by a 
intramolecular ,-migration.   
 -amino acids differ from -amino acids in that they do not elicit a response from 
proteolytic enzymes.
47
 These building blocks are of particular interest because they have 
a ‘Trojan horse’ like role in many biological processes.  Organisms find this 
characteristic advantageous when using secondary metabolites to act against foreign 
cells.  
 Fully synthetic -peptides have benefited from the lack of reactivity to proteolytic 
enzymes as well.  Several groups have shown the utility of -amino acid building blocks 
towards cellular targets.
48
 These molecules can depend on their robust nature to survive 
cellular environments.  Also, lessons can be learned from how natural systems react 
Figure 15. Several examples of the utility of -peptide scaffolds. 
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towards normal peptide sequences.  For instance, it is known that poly-arginine 
sequences enhance uptake through membrane bilayers.
49
 This reactivity is due to a 
concentration of positive charge that disrupts the membrane and allows pore formation to 
occur.  When these poly-arginine sequences were made with -arginine residues, a 
similar mechanism of action was observed.
50, 51
  
 An important lesson that can be learned from natural systems, is that peptides 
form well defined secondary structural motifs.
47
 Groups such as Gellman et al. have used 
this property to synthesize -peptides that adopt alpha helical structures.52 Once the 
periodicity of the fold is understood, amphiphilic helices can be designed.  Gellman et 
al. also have shown that such peptides are potent, and specific bacteriocidal agents 
(Figure 15).  Seebach and coworkers have also been able to mimic naturally occurring 
peptide natural products with their -amino acid counterparts.48 For instance, they were 
able to mimic the natural hormone somatostatin with a scaffold of only -amino acids.48 
By arranging the side chains in a similar way to the naturally occurring system and doing 
crystallographic studies, they were able to show similar binding affinity to natural targets 
in cells.  
 One issue with utilizing -amino acids as synthetic building blocks is that their 
synthesis is challenging.  Synthetic schemes for these building blocks are often several 
steps and give low overall yields.
53
 Routes to optically pure -amino acids include: the 
enzymatic resolution of racemates, the synthesis of perhydropyrimidin-4-ones,
54
 
conjugate addition of an amine into ,-unsaturated esters,55 and chiral sulfinimide 
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chemistry (Figure 16).
56
 However, there are no synthetic routes to obtain -amino acids 
directly from their corresponding -amino acid precursors.   
 A fascinating question is: How nature is able to synthesize these valuable building 
blocks from their -amino acid counterparts via a 1,2 amine shift (aminomutase 
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Figure 16. Several strategies for the synthesis of -amino acids are shown. (A) Enzymatic 
resolution, (B) synthesis of perhydropyrimidin-4-ones, (C) ammonia addition to ,-unsaturated 
esters, and (D) chiral sulfinimine chemistry. 
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activity)?  Four classes of enzymes are known.  Nature uses complex cofactors, to 
facilitate the -amine migration to the  position.  The first class of enzyme requires 
adenosylcobalamin and pyridoxal phosphate (PLP).
42
 An example of this is leucine 2,3-
aminomutase, which is part of the leucine catabolism pathway in humans.  The next class 
of enzyme requires PLP, an iron-sulfur cluster, and S-adenosylmethionine for catalysis.
43
 
This has been shown in Clostridium subterminale, for the conversion of L-lysine to (S)--
lysine.  The third type of enzyme requires only PLP to achieve amino migration; 
however, this is seen only in the conversion of glutamate 1-semialdehyde to -
aminolevulinic acid.
57
 Until recently, there were no examples of cofactor-independent 
enzymes responsible for -amino acid biosynthesis.  However, in 2003 Shen et al. first 
characterized SgTAM, an MIO dependent enzyme that was able to convert L-tyrosine to 
(S)--tyrosine.58  
 
1.6 MIO Dependent Aminomutases 
 In 2002 Shen and coworkers were able to successfully isolate the genes 
responsible for the biosynthesis of C-1027,
39
 the most potent antitumor/antibiotic 
compound ever isolated.
59
 This compound, isolated from Streptomyces globisporus, is a 
member of the enediyne class of natural products.  It consists of an enediyne core, an 
amino-sugar, a benzoxyzolinate, and an (S)--tyrosyl moiety.39 Upon assignment of the 
activity of certain genes based on homology models, it became evident that there was not 
a gene that encoded for one of the known classes of aminomutase that were described 
above.
42, 43, 57
  However, there was a gene present in the cluster that had high homology to 
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the class of MIO-dependent ammonia lyases (56% similarity) (Figure 17).  Shen et al. 
began to study if this enzyme could facilitate additional chemistry, to achieve the 2,3-
amino shift that would result in the formation of (S)--tyrosine.  
 
Figure 17. The alignment of various mutase and lyase enzymes. Tyrosine aminomutase from S. 
globisporus (SgTAM); Phenylalanine amionmutase from P. agglomerans (PaPAM); Histidine 
ammonia lyase from P. putida (PpHAL); and Tyrosine ammonia lyase from R. sphaeroides (RsTAL). 
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 The enzyme was cloned into an E. coli expression system, and biochemical assays 
were performed.  First, it was shown that upon incubating the enzyme with L-tyrosine, 
the 
formation of (S)--tyrosine was observed.  Observation of formation of (S)--tyrosine 
was consistent with the stereochemical assignment of the -tyrosine moiety in C-1027 
 
Figure 18. (A.) The mechanstic proposal of TAM based on the labeling studies 
of Hermes et al. in 1985 and the structural clues from the PAL structure by 
Calabrese et al. in 2004 (B.) The structure of C-1027 with a -tyrosine moiety. 
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(Figure 18).  To prove that this enzyme was responsible for the transformation, 
inactivation studies were performed that were identical to those done for the MIO-
dependent lyase family of enzymes.  Upon pre-incubation with either KCN or NaBH4, all 
detectable mutase activity was halted.  This is consistent with an active site electrophile 
being responsible for the chemical transformation.   
 Further tests were done to link this enzyme with the well-studied class of 
ammonia lyases.  It was determined that the ideal pH to achieve maximal performance of 
SgTAM was at pH 8.8.  This is consistent among all members of MIO dependent 
enzymes.  Next, Shen and coworkers investigated whether any divalent metals, or 
cofactors enhanced the rate of reaction.  It was found that nothing was needed outside of 
the native enzyme to achieve mutase activity.  In fact, the addition of several metals 
resulted in a retarded rate of reaction.  Substrate studies revealed, after testing different 
aryl derivative from phenylalanine to chlorinated and hycroxylated tyrosine, that the best 
substrate for SgTAM was L-tyrosine.  
 During investigations of the reaction of TAM with L-tyrosine, it was shown that 
4-HCA was also isolated in as much as 10% yield from the reaction.  This intermediate 
also acts as a competitive inhibitor of TAM.  This is similar to previous reports from the 
lyase family of enzymes, which showed product inhibition of HAL and PAL activity.  
Upon elongation of reaction time for TAM an increase in 4-HCA formation occurred 
(Figure 19).
60
 Once an equilibrium was achieved between  and -tyrosine, this ratio 
would remain constant and 4-HCA would keep increasing, drawing from both substrate 
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and product alike.  This activity suggested that TAM could have evolved directly from a 
lyase, without total changeover to mutase activity.   
 One interesting activity that was tested by Shen et al. was the fate of the -amine 
in the reaction.  They found that if you incubate TAM with L-3-chlorotyrosine and 4-
HCA, then (S)--tyrosine is formed after 24 hours.60 This result suggests an internal 
transfer of the amine to the product, with sequestration of ammonia in the active site.  
Since 4-HCA is a better binder than L-3-chlorotyrosine or its ,-unsaturated acid 
derivative, once the de-amination occurred, 4-HCA would bind in the active site and 
react with the bound ammonia.  To test this further, they ran a reaction with 4-HCA and 
NH4Cl for 24 hours. The result was the formation of (S)--tyrosine, but at a lesser 
 
Figure 19. The activity profile of TAM. Initially, product formation is dominant, but HCA 
formation increases with extended reaction times. 
 34
amount than the previous reaction.  These results are related to the ordered release of 
products reported previously for the lyase family of enzymes.  The characterization of an 
MIO dependent aminomutase led to a search for others of this class.  
 The first MIO dependent aminomutase from a plant source was obtained from the 
biosynthetic gene cluster of the well-known anticancer compound, taxol.
61
 Taxol was 
first isolated from the bark of the yew tree,
62
 and its commercial synthesis is a partial 
synthesis from a late stage intermediate, baccatin III.
63
 One component of taxol is a -
phenylalanine moiety.  Upon investigation of the biosynthetic gene cluster from Taxus 
chinensis, it was determined that an aminomutase from the family of MIO-dependent 
enzymes was responsible for the conversion of L-phenylalanine to (R)--phenylalanine.61 
Tests, described above, that have become synonymous with these electrophilic enzymes 
were done to ensure that this was the active catalyst.  Inactivation experiments, as well as 
pH optimization and the dependence on divalent metals and cofactors were tested.  As 
expected, KCN and NaBH4 inactivated the enzyme.  It was also shown that the pH 
optimum of the reaction was at 8.5, which again was consistent with the lyase and TAM 
family of enzymes.  Along with sequencing data, these experiments revealed that this was 
an MIO dependent enzyme.  
 Analysis of PAM reactions with phenylalanine revealed that (R)--phenylalanine 
was the product formed.  The stereoselectivity of this reaction is opposite of that 
previously reported for the TAM enzyme from S. globisporus.  Biochemical assays 
revealed that unlike the TAM reaction, there was no scrambling of the stereochemistry of 
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products after an extended period of time.  This suggests that PAM is a more efficient 
catalyst of the aminomutase reaction.   
 To test the general reactivity of PAM, a large number of commercially available 
(S)--amino arylpropanoic acids were tested for reactivity.  PAM was able to tolerate a 
large amount of structural diversity (Figure 20). Not only was it able to tolerate 
substitution on the aromatic ring, but ring contractions and hetero-atoms in the ring were 
also tolerated.  Surprisingly, (S)-styrylalanine was utilized as a substrate.  This data, 
however, proved problematic in the context of differentiating mechanisms of action.  
 
Figure 20. This shows the relatively large substrate scope that the PAM enzyme is able to tolerate. A 
relative rate is shown for the substrates with the native phenylalanine shown as a relative rate of 1.0.  
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Substitution patterns on the aromatic ring and electronic effects did not follow any 
particular pattern.  
  
 Like the lyase family of enzymes, it was unclear what the mechanism of action 
was.  It was proposed that these enzymes formed ,-unsaturated carboxylates through 
either amine activation or Friedel-Crafts type mechanisms, followed by 1,4 addition of 
ammonia to these species to yield -amino acids.  The above substrate studies, yielded 
results that were ambiguous in terms of what type of mechanism was occurring; thus 
further studies needed to be done.  
 Mutatu et al. attempted in depth deuterium labeling studies to probe what type of 
mechanism was occurring in PAM.
64
 They were unable to unambiguously say how the 
 
Figure 21. Mutatu et al. propose a Friedel-Crafts mechanism of action, with a 'syn-periplaner' 
intermediate to account for the facial selectivity of proton shuttling in PAM.  
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substrate was being activated by the MIO, but they were able to make some conclusions 
about the nature of deprotonation and amine migration.  Their work showed that the 
amine and the deprotonated benyllic hydrogen atom traded positions with facial 
selectivity.  The one issue with this, is that the (S) center of the amine and the pro(S) 
hydrogen are on opposite faces of trans-cinnamate.  To get around this problem, the 
group proposed a syn-configuration for the unsaturated intermediate (Figure 21).
64
 This 
would be the only way in which the amine and pro(S) hydrogen could maintain facial 
selectivity without the substrate rotating during the reaction sequence.  
 
1.7 Green Fluorescent Protein (GFP) and Its Relation to MIO Enzymes  
 When the structure of MIO was determined,
3
 it was recognized that the MIO 
prosthetic group was similar in structure to the GFP chromophore (Figure 22).
65
 Each 
was the result of a post-translational modification of the protein backbone that resulted in 
a tri-peptide cyclization event; with MIO formed from and Ala-Ser-Gly motif and GFP 
formed from Ser-Tyr-Gly.  Other than the structure of the cyclized peptide prosthetic 
groups, it was unclear how these proteins were related.  Their overall folds displayed no 
similarity.  The MIO-
dependent enzymes are 
primarily made up of alpha 
helices, while the GFP 
family of enzymes has a 
structure that is a -barrel 
O
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N
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RR
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MIO                                 GFP
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Figure 22. Shown are the MIO and GFP chromophores where R 
is a continuation of the peptide backbone.  
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with only a short helical region near the chromophore (Figure 23).
66
  
 When comparing the structures of the prosthetic groups, it is apparent that they 
share some commonalities in the formation of cyclized products.  The first common step 
is the attack of the backbone nitrogen of a glycine residue to the carbonyl group of a 
residue that is N+2 amino acids away.  Another common step in the formation of both 
MIO and GFP chromophores is the dehydration of the alcohol that results from that 
nucleophilic attack.  At this point, the formations of the two groups differ. In MIO 
enzymes, subsequent dehydration from the hydroxyl group of the Ser residue from the 
Ala-Ser-Gly tripeptide motif, results in the formation of the exocyclic alkene.  In the GFP 
chromophore, the auto-oxidation by molecular oxygen of the Tyr side chain of the Ser-
Tyr-Gly tripeptide sequence results in the major chromophore.  It is still not clear, in 
what order these steps occur in each protein.
67
 
 
Figure 23. The protein structures of SgTAM (PDB: 2O6Y) GFP (1EMA). TAM is shown in blue 
alpha helices while GFP is shown as primarily red beta sheets. 
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 Upon investigation of the crystal structures, and the spectroscopic differences of 
the mature prosthetic groups, it was shown that a major difference in the two 
chromophores was that the N-3 of MIO is sp
3
 hybridized, while the N-3 of GFP is sp
2
 
hybridized and lies in conjugation with the rest of its ring.  Consequently, while GFP is 
aromatic, the MIO is a non-aromatic species.  It is believed that the non-aromaticity of 
MIO enhances its reactivity as an electrophile.
18
  
 The mechanism by which the chromophores form, could result in differences 
between the two species.  It is theorized that the uncyclized GFP chromophore is favored, 
but due to orbital alignment and subsequent trapping by oxidation, the species is 
successfully made.
65
 Fully cyclized MIO is believed to be favored due to mechanical 
compression of the protein structure.
18
 Nearby residues could help to force the N-3 out of 
plan in the context of the MIO.   
 To further investigate the relationship between the two, Barondeau et al. mutated 
GFP from Aequorea victoria to have the signature tripeptide sequence found in MIO, 
Ala-Ser-Gly.
65
 When this construct was crystallized, it was observed that the MIO moiety 
had formed in the active site of GFP.  However, the N-3 of this GFP-HAL mutant was in 
plane with the ring and had formed an aromatic species.  Bond lengths and angles 
suggested that the MIO did contain an exocyclic alkene.  When the group attempted to 
add into the MIO with exogenous nucleophiles, they were unable to visualize anything 
bound to the cofactor.  This suggests that the non-aromatic nature of the MIO may be 
extremely important for its reactivity.  Further investigations between the two species 
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will need to be undertaken before an understanding of how two very similar 
chromophores can have such different functions in two different protein environments.   
 
 
1.8 Conclusion 
 A large amount of work has gone into the field of MIO-dependent enzymes.  The 
remainder of this thesis will illustrate our contributions to the field, and explain how this 
work has impacted what is known regarding the reactivity of this novel electrophilic 
prosthetic group.  
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Chapter 2: 
 
 
The Structure of L-Tyrosine 2,3-Aminomutase 
from the C-1027 Enediyne Biosynthetic 
Pathway
1
 
 
 
 
 
 
 
 
 
                                                
1 Adapted from Christianson, C.V.; Montavon, T.J.; Van Lanen, S.G.; Shen, B.; Bruner, 
S.D. Biochemistry 2007, 46, 7205-7214. 
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2.1 Introduction 
 Enediynes are chromoprotein antitumor/antibiotic natural products produced 
mainly by Streptomyces bacteria (Figure 1).
1
 The potent DNA-cleaving ability and 
unique mechanism of action of these natural products make them promising leads for 
 
Figure 1. (S)--Tyrosine biosynthesis in enediyne natural products (A) The structure of C-1027 with the 
(S)--tyrosine moiety highlighted.  (B) The structure of the MIO cofactor formed by condensation of an 
Ala-Ser-Gly motif present in SgTAM. (C) Two reaction pathways for a MIO-based aminomutase based on 
the proposed mechanistic schemes for MIO-based ammonia lyases. 
novel therapeutic agents.  Enediynes are produced by complex enzyme pathways 
containing components of both polyketide and nonribosomal peptide machinery.
2-5
 The 
biosynthetic routes of these molecules are largely convergent, incorporating building 
blocks derived from amino acids, polyketides and carbohydrates around a central 
enediyne core.  Several enediynes contain -tyrosine moieties as structural components 
and the aromatic functionality is predicted to interact with the enediyne and modulate the 
Bergman cyclization leading to diradical formation and biological activity.
6
 The enediyne 
C-1027, produced by Streptomyces globisporus, incorporates a 3-chloro-5-hydroxy--
tyrosine in its complex architecture.
2
 The biosynthetic pathway to this -amino acid 
 52
begins with the conversion of -tyrosine to -tyrosine catalyzed by a 2,3-tyrosine 
aminomutase (SgTAM).
7, 8
 
 The aminomutase class of enzymes catalyze the 1,2-shift of substrate amines in a 
variety of secondary metabolic pathways.  In general, characterized aminomutases rely 
on complex cofactor chemistry, using radical-based mechanisms to perform this difficult 
transformation.
9
 For example, lysine 2,3-aminomutase is a ‘radical-SAM’ enzyme 
dependent on S-adenosylmethionine, an iron–sulfur cluster and pyridoxal 5'-phosphate as 
cofactors.
10
 The mechanism is believed to proceed through a Schiff-base mediated 1,2 
shift of a radical intermediate.  Other structurally characterized examples of 
aminomutases use cobalamin and pyridoxal 5'-phosphate and follow a similar reaction 
pathway.
11
 Sequence analysis of the biosynthetic gene cluster for the enediyne C-1027 
revealed a novel class of aminomutase with a catalytic mechanism dependant on the 
uncommon prosthetic group 4-methylideneimidazole-5-one (MIO).
2
   
 -Amino acids are important and useful building blocks in both natural and 
unnatural peptidic systems.
12, 13
 Besides enediyne pathways, MIO-based aminomutases 
are responsible for the synthesis of -amino acids incorporated into other classes of 
natural products.  For example in taxane biosynthesis, a phenylalanine aminomutase is 
responsible for the formation of a key building block in the taxane sidechain
14
 and the 
biosynthetic gene cluster of the mixed polyketide/nonribosomal peptide andrimid 
contains a predicted MIO-based phenylalanine aminomutase.
15
 
 The MIO cofactor is formed by the condensation of a conserved Ala-Ser-Gly 
motif present in the protein backbone.
16
 The self-catalyzed reaction is chemically 
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analogous to the formation of the chromophore present in the green fluorescent protein.
17
 
The histidine ammonia lyase (HAL) family of enzymes contains a well-characterized 
MIO cofactor.
16
 Members of the HAL family catalyze the elimination of ammonia from 
aromatic -amino acids, a process important in amino acid catabolism and secondary 
metabolism.
18, 19
 Known substrates of MIO-based ammonia lyases include the aromatic 
amino acids: tyrosine, phenylalanine and histidine.   Recently, X-ray structures of several 
members from this family have been determined including a HAL structure from P. 
putida;
20
 phenylalanine ammonia lyase (PAL) structures from P. crispum
21
 and  R. 
toruloides
22
 and tyrosine ammonia lyase (TAL) from R. sphaeroides.
23
 The structures 
reveal a common motif where the monomer subunits are composed largely of -helices 
with the MIO cofactor positioned at the termini of multiple helices.  The biologically 
active subunit is tetrameric where the monomers are related by 222 symmetry.  The 
composite active site is at the junction of monomers, and the four catalytic centers each 
contain amino acid sidechains from three of the four subunits. 
 As discussed in the introduction chapter, two debated mechanisms have been 
proposed to account for the MIO-catalyzed elimination of ammonia observed in the HAL 
family.
24, 25
 The highly electrophilic MIO cofactor is postulated to react with either the 
aromatic ring or the amine of the amino acid substrate.  Both mechanisms lead to 
acidification of the -hydrogens and subsequent elimination of ammonia to generate the 
observed products.  Based on sequence homology of the SgTAM tyrosine aminomutase 
to the HAL family, a related mechanism has been proposed to account for the observed 
1,2 amino shift (Figure 1 C).
7
   In the first step, analogous to ammonia lyases, ammonia is 
 54
eliminated to generate an intermediate coumarate.  Subsequent 1,4-addition of ammonia 
into this intermediate leads to -tyrosine.   Based on this hypothesis, an MIO-based 
aminomutase must minimally retain ammonia in the active site and activate the relatively 
non-electrophilic coumarate intermediate for nucleophilic addition.  The structural and 
mechanistic basis for the differentiation between MIO-based ammonia lyases and 
aminomutases has not been 
established. 
 Our work represents the first 
report of an MIO-based aminomutase.  
The 2.5 Å resolution structure 
confirms that MIO-based 
aminomutases are structurally 
homologous to the HAL-family of 
ammonia lyases.  The structural 
information allows insights into the 
mechanistic differences between 
aminomutases and ammonia lyases.  
Comparisons between SgTAM and a 
homologous tyrosine ammonia lyase are exploited to better understand the mechanism of 
the MIO-based aminomutase activity.   The results reveal the structural basis for substrate 
recognition and catalysis. In addition to providing information on the mechanism of -
Figure 2. Isolation and purification of SgTAM. (A) 
After lysing cells, protein was obtained in two elutions 
off of Ni resin. (B) After the addition of TMAO to 
crystallization conditions, larger crystals were 
obtained. 
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tyrosine formation, this work represents the first structural details into the biosynthetic 
pathway of antitumor enediynes, a proposed target of bioengineering.
1
   
 
 
Figure 3. Sequence alignment of representative MIO-based aminomutases and ammonia lyases. 
The secondary structure corresponding to SgTAM is illustrated above the sequences.  The three 
residues that form the active site MIO are boxed in green and the inner and outer loop regions are 
indicated below the sequences.   Sequences were aligned using the ClustalW pairwise alignment 
protocol.  Abbreviations used: SgTAM, S. globisporus L-tyrosine aminomutase; PaPAM, P. 
agglomerans L-phenylalanine aminomutase; PpHAL, P. putida L-histidine ammonia lyase; 
RsTAL, R. sphaeroides L-tyrosine ammonia lyase. 
 56
2.2 Crystallization and Structure Determination of the Tyrosine Aminomutase 
SgTAM 
 The aminomutase from the enediyne C-1027 gene cluster was overexpressed in E. 
coli and purified.
7, 8
   For crystallization, the affinity tag was removed via proteolysis and 
the enzyme was purified using two chromatography steps as described in the materials 
and methods section.  The protein was monitored by an HPLC-based biochemical assay 
at various points during the purification and crystallization process to ensure its full 
activity.  An amount of 10-20mg of SgTAM was obtained per liter of harvested E. coli 
cells after the cleavage and two chromatographic steps (Figure 2).  Crystal screens 
showed that SgTAM was able to form needle-like crystals with Sodium Formate, but they 
were too small to yield usable diffraction data.  By investigating different additive 
screens, trimethylamine-N-oxide (TMAO) was found to promote larger needle formation 
(Figure 2 B).  SgTAM crystallized in the space group P21212 with two ~58 kDa 
monomers per asymmetric unit.   Initial phase information used to solve the structure was 
obtained using molecular replacement techniques.  Histidine ammonia lyase from P. 
putida (36% sequence identity) was selected as a search model based on predicted 
common structural motifs (Figure 3).
20
 A polyalanine model of the HAL monomer was 
used to generate initial phase information to solve the structure.  The correct solution had 
a preliminary R-value of 0.51.  The model of SgTAM was built into the density maps and 
refined to 2.5 Å resolution (Table 1).  The two monomers of the asymmetric unit are very 
similar with a root-mean-squared difference between equivalent backbone atoms of 1.17 
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Å.  The final model contains residues 12-539 and 11-539 in the two respective 
monomers. 
 
2.3 The Overall Structure of SgTAM   
 The structure of SgTAM (Figure 4) displays homology to the core structures of 
ammonia lyases.  Symmetry operations in the unit cell generate a head-to-tail dimer of 
dimers related by 222 point symmetry.   The active, biological unit of SgTAM is assigned 
as a tetramer based on homology with the HAL superfamily of ammonia lyases.   The 
total buried surface area is significant and calculated to be 8,400 Å
2
 per SgTAM 
monomer.  The overall structure is largely -helical with most helices running along the 
long axis of the monomer structure (Figure 4C).   There is a single -sheet in the 
monomer, composed of two short strands.  A second -sheet forms in the tetramer from 
two -strands in adjacent monomers.  These two short strands precede helices -3 and -
15 in the monomer structure.   The active site is located close to one end of the monomer 
structure near the termini of several -helices and is situated at the positive end of several 
helix dipoles.  Specifically the ends of helices -6, -9, -15 and -17 are directed at the 
MIO cofactor, a feature common in MIO-based ammonia lyases.
22
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Crystal Form Primitive Orthorhombic 
PDB code 2OHY 
beam line NSLS X26C 
wavelength 0.9795 
space group P21212 
cell dimensions 92.597, 146.178, 75.437 
resolution of structure 50.0-2.50 (2.59-2.50) 
unique reflections 35786 (3515) 
completeness 99.9 (99.7) 
redundancy 6.0 (5.9) 
I/Sigma(I) 18.6 (4.1) 
Rmerge (%) 9.4 (53.4) 
monomers per asymmetric unit 2 
solvent content (%) 40.39 
amino acid residues 1057 
# of non-hydrogen atoms 8021 
water molecules 417 
Rworking/Rfree 0.192/0.264 
rmsd of bond lengths 0.0057 
rmsd of bond angles 1.267 
average B-factor  29.56 
Table 1.  X-ray data collection and refinement statistics.  Statistics in the highest data bin are shown in 
parentheses.  
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2.4 The Active Site Containing MIO  
 The MIO cofactor in SgTAM is formed by the self-condensation of Ala152, 
Ser153 and Gly154.   The MIO is clearly formed in our structure based on examination of 
the electron density maps (Figure 5).  The two active sites present in our asymmetric unit 
are very similar in both the orientation of the MIO and adjacent side chains.  From 
 
Figure 4. The X-ray structure of the L-tyrosine 2,3-aminomutase, SgTAM.  (A)  Structure of 
the tetramer with each monomer distinctly colored.  The views are looking along the two axes of 
symmetry.  The location of the active site is indicated by the four red spheres.   (B) Structure of 
the SgTAM monomer. The secondary structure elements are labeled.  The MIO cofactor is 
colored in red and the loops regions surrounding the active site are indicated. 
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examination of the composite omit electron density maps, orphan density is evident at 
higher sigma levels contiguous with the methylidene group of the MIO cofactor.  This 
suggests partial occupancy of a small molecule nucleophile complexed to the 
electrophilic MIO.   It has been observed in previous structures of ammonia lyases that 
nucleophiles can react with the MIO.  For example, in the presence of cysteine, a 
covalent complex of the histidine ammonia lyases is formed with the thiol group of the 
amino acid.
26
 -mercaptoethanol was present during our enzyme purification steps and 
this thiol models well into the extra electron density as a covalent adduct with the MIO 
cofactor.  The addition of -mercaptoethanol into the MIO appears to be reversible as the 
enzyme retains biochemical activity under the conditions utilized during purification 
(Figure 5B).   Though the pH used is not optimal for enzyme activity, turnover is still 
observed in a 120 minute reaction.  In addition, the published biochemical conditions 
contained dithiothreitol, likely able to react with the MIO.  We cannot, however, rule out 
the possibility that the observed activity results from the enzyme fraction with an 
unmodified MIO.  
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  The active site is located at the subunit junction of the SgTAM tetramer.  Amino 
acid sidechains from three of the four monomers come together to generate a composite 
active site.   The area immediately surrounding the MIO is comprised largely of aromatic 
side chains, including Tyr63 and His93 from the A monomer, Tyr308 from the B 
monomer and Tyr415 from the C monomer (the A monomer is defined as the chain 
 
Figure 5. The active site of SgTAM.  (A)  Electron density map around the MIO cofactor.  The map is 
scaled at 2.0 (black) and 1.5 (green).   (B) HPLC trace showing the conversion of L-tyrosine to (S)--
tyrosine catalyzed by SgTAM under the crystallization conditions.  The OPA-amino acid derivatives are 
monitored at 335 nm on a C18 reverse-phase column. (C) Superposition of the active sites of SgTAM 
with the L-tyrosine ammonia lyase, RsTAL (pdb# 2O6Y).   The stereoview showing the amino acid 
sidechains in close proximity to the MIO cofactor.   Residues and labels corresponding to SgTAM are 
colored dark grey and RsTAL light grey. 
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containing the MIO cofactor).  In addition, the polar sidechains of Asn205, Gln438 and 
Gln442 from the A chain and Arg311 from the B chain are in proximity to the MIO 
center (Figure 5B).   Residues implicated in MIO formation for the HAL ammonia lyases 
are structurally conserved in SgTAM.
27
 For example, Phe356 corresponds to Phe329 in 
HAL, a residue proposed to play a key role in the autocatalytic formation of MIO.  It is 
believed that the formation of MIO is achieved through mechanical compression of the 
peptide backbone.
17
  
 The active site of SgTAM with bound -mercaptoethanol is in a ‘closed’ 
conformation as defined by the structures of ammonia lyases.  Based on previous 
structural work the ‘open’ form predominates without substrate or analogs in the active 
site.
20-23, 26, 28
 Two protein loops cover the active site in the HAL enzyme family and are 
proposed to play important roles in substrate binding and catalysis.
29
 An inner loop 
contributes side chain functionality to the active site and an outer loop further covers and 
protects the reactive active site center.  In the structure of SgTAM, the inner loop 
corresponds to residues 56-84 and the outer loop to residues 271-308 (Figure 3 and 4C).  
The inner loop is close in proximity to the MIO, placing the 4-OH of Tyr63 within 5.6 Å 
of the methylidene carbon of MIO.   This tyrosine forms a hydrogen bond with Gly70 
and both residues are conserved in all MIO-containing homologs.   As compared to the 
tyrosine ammonia lyase from R. sphaeroides (RsTAL) and other ammonia lyase 
structures, the active site loops of SgTAM are in general longer (Figure 3) and contain 
more secondary structure elements.   As illustrated in Figure 3C, an -helix (-13) is 
formed in the outer loop and a short two-strand, -sheet forms between the outer loop of 
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one monomer with the inner loop of another.  These structural elements contribute to an 
ordered and closed active site as discussed below. 
 
Figure 6. Accessibility of the active site of SgTAM as compared with the tyrosine ammonia lyase 
RsTAL.  (A and B):  Cutaway view of the area leading from the surface to the MIO. The solvent 
accessible surface was generated using a probe sphere radius of 1.4 Å.  The MIO cofactor is colored red 
in licorice representation.  (C and D):  View of the active site from the surface.  Key side chains are 
illustrated.  (E and F):  Ribbon cartoon representation comparing the loops regions of SgTAM with 
RsTAL 
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2.5 Comparison of the SgTAM Active Site With Tyrosine Ammonia Lyase  
 The tyrosine ammonia lyase, RsTAL, shares the same substrate as SgTAM and 
the enzymes are 38% identical at the amino acid level.
23
 The overlay of the active site of 
SgTAM and the tyrosine ammonia lyase from R. sphaeroides (RsTAL; pdb code 2O6Y) 
is shown in Figure 5B.  Overall the active sites exhibit a very similar architecture.  The 
MIO cofactor is in approximately the same orientation in each of the structures and 
amino acid side chains surrounding the MIO are largely conserved amongst the two 
structures.  The single prominent difference in the side chains is the presence of Tyr415 
in SgTAM where in RsTAL Val409 occupies this position. 
 
2.6 Restricted Active Site of SgTAM  
 Translating the general reaction mechanism of ammonia lyases to SgTAM 
predicts the production of the intermediates coumarate and free ammonia (Figure 1C).  
Biochemical experiments support this reaction pathway as coumarate is a product of 
SgTAM reaction for extended reaction times (8).
8
 Based on this mechanism, an efficient 
aminomutase would be expected to retain free ammonia in the active site and sequester it 
in the neutral, nucleophilic state.  From comparison of the active sites of SgTAM with 
RsTAL (and other ammonia lyases), the active site of the aminomutase lacks accessibility 
to the solvent as present in ammonia lyases (Figure 6).  The active sites of ammonia 
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lyases are accessible to bulk solvent through an opening in the loops forming a small 
channel (Figure 6B).  Solvent accessibility from the MIO to the protein surface is not 
apparent in SgTAM (Figure 6).   Two residues appear particularly important in blocking 
access to the active site; Tyr303 and Glu71 form a hydrogen-bonding interaction across 
the channel, an interaction not present in RsTAL or other lyase structures. As illustrated, 
in ammonia lyases the MIO cofactor is visible from the surface through a small channel 
(Figure 6B).  This feature could function to facilitate diffusion of ammonia/ammonium 
out of the lyase active site.   The same views of SgTAM suggest an enclosed active site 
(Figure 6A,B).    In addition, as discussed above, the inner and outer loops of SgTAM 
contain additional secondary structure elements not present in ammonia lyase structures 
further shielding the active site with ordered loops (Figure 6C). 
 
2.7 Recognition of the Substrate Tyrosine in SgTAM 
 Based on the strong structural homology to tyrosine ammonia lyase, the residues 
involved in substrate recognition in SgTAM can be predicted.  A model (Figure 7) of 
tyrosine bound in the active site of SgTAM was prepared by superposition of the 
RsTAL/2-aminoindan-2-phosphonic acid (AIP) structure (pdb code 2O7E)
23, 30
 and 
overlay of tyrosine on to the position of AIP with minimal modification.  We chose to 
model tyrosine as the amine complex with MIO based on the significant homology and 
structural overlap with the RsTAL/AIP structure.  The binding mode is consistent with 
one of the two debated mechanistic hypotheses in the literature.
23
 Tyrosine fits well into 
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the aminomutase active site and the model confirms amino acid residues important for 
chemistry and recognition.  Notably, the position of His89 (in RsTAL) has been 
established as a key recognition element in ammonia lyases.
23, 31
 Mutation of this side 
chain allows alteration of the preferred amino acid substrate.  In SgTAM, this position 
(His93) is also structurally conserved and the 4-OH of the modeled substrate tyrosine is 
within hydrogen bonding distance of the histidine.  Tyr415 is also within hydrogen bond 
distance of the substrate 4-OH, indicating a possible role for this sidechain.  Residues 
corresponding to Tyr415 are not present in RsTAL or other ammonia lyases.  Additional 
conserved residues in SgTAM that can be predicted to interact with the substrate are 
 
Figure 7.  Model of the substrate L-tyrosine bound in the active site of SgTAM.  Based on the high 
structure homology with RsTAL, the substrate was modeled into the SgTAM structure by 
superposition of L-tyrosine with the bound analog in the AIP/RsTAL co-complex (pdb# 2O7E). 
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Arg311 and Asn205, both in the proper position to interact with the carboxylate of the 
substrate amino acid.   
 
 
2.8 Mechanistic Implications From the Structure of SgTAM 
 The chemical mechanism of MIO-based enzymes is actively debated and has not 
entirely been resolved.
24
   A large amount of biochemical, structural and model system 
approaches have focused on two alternate roles where the MIO cofactor activates the 
aromatic ring or the amino group of the amino acid substrate.  The rationale in both cases 
is to acidify the substrate -proton to allow deprotonation and elimination of ammonia.   
Following the reaction scheme of lyases, an MIO-based aminomutase faces the additional 
challenge of catalyzing the coupling of ammonia into the conjugated coumarate 
intermediate.  Any mechanistic hypothesis requires abstraction of the -proton/hydrogen 
from -tyrosine.  The best candidate for a catalytic residue in SgTAM to play this role is 
Tyr63.  This tyrosine forms a hydrogen bond with the backbone of Gly70.  Both residues 
are conserved at this position in all MIO-based ammonia lyases and aminomutases.  
Tyrosine 308 is also positioned near the MIO in the active site and its 4-OH models close 
to the -hydrogen of the substrate tyrosine.   Tyr63 and Tyr308 are reasonable candidates 
to assist in the transfer of hydrogen atom from the - to -position in tyrosine as required 
by the aminomutase chemistry.   The precise role of the MIO cofactor in the chemistry of 
aminomutases remains to be elucidated.  The implication of the positive helical dipoles in 
the active site may disfavor a carbocation-based mechanism.
22
 The small number of 
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characterized MIO-containing enzymes has limited the generation of general hypotheses 
into the precise role of the cofactor.  This is especially apparent when the mechanistic 
theories are translated to the chemistry of aminomutases.   
 
2.9 Comparison of SgTAM Active Site With Green Fluorescent Protein 
 From the initial structural determination of the MIO cofactor,
20
 it was known that 
the GFP chromophore was the most structurally similar biological entity (Figure 8).
32
 
Mutational studies allowed access to a MIO-like mutant of GFP from Aequorea victoria 
(GFPmio).
17
 Due to the extreme differences in the two proteins overall architecture, a 
functioning MIO was unachievable in this system.  The engineered MIO in GFP was 
unable to form a complex with small nucleophiles.  For having such similar 
chromophores, the active site environments are totally different.  It is thought that MIO is 
formed due to mechanical packing constraints and favors a cyclic product,
27
 whereas the 
GFP prosthetic group favors a linear orientation of the tri-peptide motif, but upon 
oxidation is trapped in the ring closed state.
17
 One clue that points to the increased 
mechanical stress of the MIO system, is that the N-3 of the MIO is pushed out of 
planarity with the ,-unsaturated system, thus making the system non-aromatic.20  In 
GFP, the N-3 is in plane and the subsequent aromatic system allows for the interesting 
spectral properties of GFP that make it so useful.
33
 We were interested to see if we can 
perform the orthogonal experiment, mutation of an MIO-enzyme into a GFP 
chromophore.  Therefore, we mutated the active site Ser to a Tyr in hopes of visualizing 
GFP-like properties in the SgTAM system.  Mutation was shown to be successful by 
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sequence analysis, and protein 
was generated at the correct 
size, but florescence was never 
detected (Figure 8B).  Attempts 
were made to crystallize this 
system, but no viable crystal 
hits were obtained.  Further 
studies will be done to see if 
the active site can 
accommodate this mutation.  
One important difference 
between MIO-dependent 
enzymes and GFPs, is that the 
GFP is formed by oxidation, 
while the formation of MIO is the result of two dehydration steps.  This might inhibit the 
formation of an active GFP chromophore in the SgTAM system, especially with a 
‘closed’ active site preventing free access to molecular oxygen.  Structural data will be 
required to determine if this is true.  
 
 
 
 
Figure 8. (A) The structures of the MIO and GFP 
chromophores where R is a continuation of the peptide 
backbone. (B) A gel showing the purification of SgTAM 
S153Y mutant. 
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Materials and Methods 
 
Biochemical Isolation of SgTAM 
 The sgcC4 gene which encodes for SgTAM was amplified from pBS1005
8
 by 
PCR using a 5’-TGA ATT CCA TAT GGC ATT GAC TCA AGT CGA GAC-3’ 
forward primer (the EcoRI site is underlined and the NdeI site is shown in bold) and a 5’-
AAT AAG CTT TCA GCG CAG CTG GAT GTC CGT CTC-3’ reverse primer (the 
HindIII site is shown in bold).  The resultant product was cloned into the EcoRI-HindIII 
sites of pGEM-3zf(+) to yield pBS1023.  The sgcC4 gene was then moved as a 1.7 kb 
NdeI-HindIII fragment from pBS1023 into the same sites of pET28a to afford pBS1022.8 
The latter construct resulted in the production of SgTAM, upon incorporation into E. coli 
BL21(DE3) cells, as an N-terminal His6-tagged fusion protein.  
 
Enzyme Production  
 SgTAM (58 kDa, 539 amino acids) from Streptomyces globisporus (ATCC 
15944), cloned in the pET28a vector, (generously provided by B. Shen, U. Wisconsin, 
Madison) was transformed into BL21(DE3) cells and grown in LB media at 37 ˚C until 
cell density reached O.D. = 0.6.
7, 8
 Overexpression was induced by adding IPTG (50 
mM), followed by overnight incubation at 18 ˚C.  Cells were pelleted by centrifugation 
and lysed using a French Press cell disruption system.  The enzyme was purified with Ni-
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NTA affinity resin (Qiagen), followed by cleavage of the hexa-histidine tag with the 
protease thrombin (2 days at 4 ˚C).  Further purification was performed with a HiTrap-Q 
ion exchange column followed by a Superdex 200 gel filtration column (GE 
Biosciences). 
 
Crystallization and Data Collection  
 Initial crystal hits of SgTAM were obtained by screening with the Hampton 
Crystal Screens I and II (Hampton Research).  SgTAM was crystallized by the hanging 
drop vapor diffusion method at 4 ˚C.  SgTAM (1.5 μL of 10 mg/mL in 20 mM Tris-HCl, 
1 mM -mercaptoethanol and 100 mM NaCl, pH 7.5) was mixed with 1.5 μL of reservoir 
solution (4.4 M sodium formate, 100 mM trimethylamine N-oxide).  Needle shaped 
crystals appeared within two days and were allowed to continue growth for 
approximately one week.  Crystals were transferred to a cryoprotectant solution of the 
reservoir solution with 20% glycerol and briefly soaked before being flash frozen in 
liquid nitrogen.  X-ray diffraction data was collected on the X26C beamline at the 
National Synchrotron Light Source at Brookhaven National Laboratory on an ADSC 
Quantum 4 CCD detector at 100˚ K.  Diffraction intensities were indexed, integrated, and 
scaled with HKL2000
34
 as summarized in Table 1.  The crystal belongs to the space 
group P21212, with unit cell dimensions: a=92.6 Å, b=146.2 Å, c=75.4 Å and === 
90˚.  
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Structure Determination   
 The initial structure solution was obtained by a molecular replacement approach.  
From sequence analysis of MIO-based lyases, histidine ammonia lyase (pdb code: 1B8F) 
was chosen as an initial search model based on homology to SgTAM.   A polyalanine 
model of the histidine ammonia lyase monomer was used to generate initial solutions 
using the programs AMORE and MOLREP.
35, 36
 Multiple solutions were screened and 
evaluated based on the ability to form symmetry-related tetramers consistent with the 
biological unit.    
 
Model Building and Refinement   
 Model building was performed with the program COOT
37
 using the initial 
polyalanine HAL solution as a guide. Refinement cycles and generation of electron 
density maps were done using the CNS suite of programs.
38
 The parameter and protein 
topology files were modified to incorporate the MIO moiety into the protein backbone 
structure. Cycles of rigid body refinement and simulated annealing guided by -weighted 
composite omit maps were carried out until the R-values were no longer improved to any 
extent. The program Pymol (Delano Scientific, San Carlos, CA) was used to generate 
graphic images. 
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Biochemical assay of SgTAM   
 The biochemical activity of SgTAM was confirmed by using an HPLC based 
assay with modifications.8 Reactions were performed at 25 °C with 100 μM L-tyrosine in 
20 mM Tris-HCl, 100mM NaCl, 100 μM -mercaptoethanol and 0.5 mg/mL of SgTAM 
at pH 7.5.  Aliquots from the reaction were quenched by the addition of 0.2 M HCl until 
the pH=2.0.  The enzyme was then removed by centrifugation. The supernatant was 
returned to pH 9.0 by the addition of 0.25 M NaOH. OPA derivatives of the reaction 
mixture were obtained by mixing an equal volume of OPA reagent (16 mg o-
phtalaldehyde in 200 μL of ethanol, 44 μL of -mercaptoethanol, and 17 mL of 100 mM 
sodium borate pH 10.7) with neutralized aliquots for 1 minute followed by the addition of 
1 % v/v acetic acid. After derivation, the mixture was analyzed by HPLC C18 
chromatography using gradients of eluent A: 5 mM sodium acetate (pH 5.7) in 95:5 
H2O/THF and eluent B:  5 mM sodium acetate (pH 5.7) in 45:45:10 
methanol/acetonitrile/water. 
 
Generation of SgTAM S153Y Mutation 
 The S153Y mutation was introduced into the active site by the Quikchange site-
directed mutagenesis protocol. (Strategene) The S153Y mutation was introduced with the 
following primer pair: 5-CAC TCG GGG CGT ACG GCG ACC TGG C-3 and 3-GCC 
AGG TCG CCG TAC GCC CCG AGT G-5 (with the S153Y mutant in bold). Several 
modifications to the Quikchange protocol were made to successfully generate mutations 
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to SgTAM. Reaction mixtures consisted of the following: 100 ng of template DNA, 500 
ng of each primer, 200 μM dNTPs, 5% (v/v) DMSO, 1x buffer, and 1 unit of Pfu 
polymerase in a final volume of 100 μL. The PCR program was the following: initial 
denaturing at 95 ˚C for 5 min, followed by 35 cycles at 95 ˚C for 30 s, 62 ˚C for 45 s, and 
72 ˚C for 10 min, and completed by an additional 10 min at 72 ˚C. Following the PCR, 
20 units of DpnI was added directly into the reaction and incubated at 37 ˚C for 2 hr. The 
entire digested reaction mixture was cleaned using a Quiagen PCR purification kit and 
then cyclized overnight by the addition of 400 units of T4 DNA ligase at 16 ˚C. The 
reaction mixture was transformed into NovaBlue Singles (Novagen). The S153Y mutant 
was confirmed by sequencing the full SgTAM coding region. Following sequence 
confirmation, the S153Y construct was transformed into BL21 (DE3). 
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Chapter 3: 
 
 
The Mechanism of L-Tyrosine 2,3-
Aminomutase and MIO  
Dependent Enzymes
1
 
 
 
 
 
 
 
 
                                                
1 Adapted from Christianson, C.V.; Montavon, T.J.; Festin, G.M.; Cooke, H.A.; Shen, B.; 
Bruner, S.D. J. Am. Chem. Soc. 2007, 129, 15744-5. 
Montavon, T.J.; Christianson, C.V.; Festin, G.M.; Shen, B.; Bruner, S.D. Bioorg. Med. 
Chem. Lett. 2008, 18, 3099-3102. 
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3.1 Introduction 
  -Amino acids are important building blocks in a variety of polymers and small 
molecules. 2,3-Aminomutases catalyze the direct conversion of proteinogenic -amino 
acids to -amino acids.1, 2 A subset of this enzyme class is dependent on the uncommon 
prosthetic group 4-methylideneimidazole-5-one (MIO) and utilizes aromatic -amino 
acids as substrates.
3, 4
 Natural product biosynthetic pathways for enediynes, taxanes, and 
nonribosomal peptides contain MIO-based aminomutases.
3, 5-7
 As described in the 
preceeding chapter, we have determined the X-ray structure of tyrosine aminomutase 
(SgTAM) from the enediyne C-1027 producer Streptomyces globisporus.
8
 The X-ray 
results established that MIO-based aminomutases are structural homologs to ammonia 
lyases, and the prosthetic group is unique to these classes of enzymes.
9
 The mechanism of 
MIO-based ammonia lyases has been extensively studied; however, the role of the MIO 
in the chemistry is actively debated and not entirely resolved.
9, 10
 As outlined in chapter 1, 
two mechanisms have been proposed for MIO-catalyzed elimination of ammonia in -
Figure 1. Mechanistic proposals for MIO-based enzymes 
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amino acids.  The primary obstacle the enzyme overcomes is removal of a relatively 
nonacidic -hydrogen.  The highly electrophilic cofactor has been postulated to react 
either with the -amino group (path A) or the aromatic ring (path B) to generate the two 
covalent adducts shown in Figure 1 (1 or 4). Both pathways lead to deprotonation and 
elimination (2 or 6) of ammonia to form a conjugated olefin.  Based upon high structural 
homology to lyases, the mechanism of aminomutases is likely an extension of the lyase 
chemistry with readdition of the amine via 1,4-conjugate addition.
4, 8 
Supporting this 
mechanism, aminomutase activity has been determined to proceed through a cinnamate 
intermediate and is reversible.
 
 Any potential 2,3-aminomutase mechanism must account for the reversible nature 
of this reaction, and provide an explanation of how an enzymatic system gains the ability 
to remove the - and -hydrogens to achieve this process.  Described herein is the 
design, synthesis and characterization of two classes of mechanism-based inhibitors for 
the tyrosine aminomutase SgTAM.  
 
3.2 Mechanistic Probes of SgTAM 
 The substrate or product analogs were designed to form covalent adducts with the 
MIO, mimicking intermediates along the reaction pathway.  Any potential 2,3-
aminomutase mechanism would proceed through abstraction of the - and/or -
hydrogens of the substrate.  In order to gain insight into the chemistry, it would be best to 
irreversibly bind the MIO to facilitate crystallization in the presence of inhibitor.  
Attempts have been made to crystallize MIO-dependent enzymes in the presence of their 
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substrates or products to no avail.
11
 A species with a longer lived covalent modification 
of MIO is required.  With this consideration in mind, it is also important to learn as much 
about substrate recognition by making the mechanistic probes as close to the natural 
compounds as possible.  Inhibitors resembling substrates or intermediates, along the 
reaction pathway, that cannot be converted to additional products, would provide the 
most information concerning substrate binding and catalysis 
 The first family of compounds that we investigated were analogs based on the 
structure of the product, (S)--tyrosine.  In order to generate a stable mechanistic probe 
 
Figure 2. Structures of tyrosine aminomutase inhibitors based on cinnamate epoxides (7a-
c) and ,-difluoro--tyrosine (8a-c).  The proposed binding mode for each inhibitor class is 
illustrated. 
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for SgTAM, we exploited -Tyr analogs with fluorine atoms substituted for the -
hydrogens.  ,-Difluoro-(S)--tyrosine 11 would provide an informative trapped 
mechanistic probe for either of the two mechanistic scenarios. The inclusion of -
fluorines in 8a prevents the reverse reaction [(S)--tyrosine to L-tyrosine] and generates a 
product-like intermediate co-complex (Figure 2, 11).  This co-complex should provide 
information on how the enzyme recognizes and binds (S)--tyrosine.  To date, substrate 
recognition events have been based on mutational studies and binding to ,-unsaturated 
acids in TAL; thus, visualizing how mechanistic probes bind would be a significant 
advance in the field.   
 It was also important to determine how TAM binds to molecules resembling L-
tyrosine and cinnamate.  Analogs based on cinnamate epoxides (7a-c) were designed to 
mimic the para-hydroxycinnamate intermediate in the reaction while presenting a 
reactive functionality to the active site.  This design rationale is based on the similar 
geometry of the epoxide to the double bond in para-hydroxycinnamate. Thus, it is 
possible that these inhibitors could bind in a similar manner to cinnamate and present a 
reactive functional group to act as a mechanistic trap (Figure 2, 10).  If activation of the 
aromatic ring occurs, the epoxide should open up when elimination of the amine would 
occur.  However, if amine activation occurs in the natural system, an opening of the 
epoxide might occur upon addition into the MIO.  In addition to being a mechanistic trap, 
the stereochemistry of the epoxide mimics that of both L-tyrosine and (S)--tyrosine.  
This should illustrate interactions with surrounding amino acid side chains that are 
important for both substrate and product binding.  Not only will crystal structures of these 
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molecules bond to TAM reveal how MIO activates substrates; such data will also reveal 
residues important for catalysis and recognition. 
   
3.3 Synthesis of SgTAM Substrate Analogs 
 The synthesis of ,-difluoro analogs (8a-c) follows published work using 
Ellman’s sulfinamide chemistry to prepare ,-difluoro--phenylalanines.12, 13 The 
synthesis of 8c is 
summarized in 
Scheme 1 as an 
example.  Briefly, 
the route starts with 
benzaldehyde (or 4-
substituted 
benzaldehydes), 
which is condensed with (R)-tert-butylsulfonamide.
14
 A highly diastereoselective 
Reformatsky-type addition of BrZnCF2CO2Et followed by global deprotection yields the 
desired -tyrosine analogs.  The ability to couple functionalized 4-substituted 
benzaldehyde allows access to a large range of substrates.  The promiscuity of TAM 
could easily be tested with commercially available starting materials. 
 The synthesis of epoxide-containing analogs (7a-c) begins with various para-
substituted ethyl cinnamates (14a-c, Scheme 2).  Enantioselective epoxidation with Shi’s 
catalyst efficiently produced the desired epoxides.
15
 Finally, saponification of the ethyl 
R
O H
a,b
HN
R
S
O
CO2Et
FF
+
H3N
R
CO2
-
FF
c,d
12a R=OTBS
12b R=OMe
12c R=H
13a R=OTBS
13b R=OMe
13c R=H
8a R=OH
8b R=OMe
8c R=H  
 
Scheme 1. Synthesis and evaluation of SgTAM mechanistic probes. a) (R)-t-
butylsulfinimine, CsCO3, DCM. b) Zn0, ethyl bromodifluoroacetate, THF. c) 6N HCl, . 
d) i-PrOH, propylene oxide. 
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ester protecting group gave the desired analogs as potassium salts.  As opposed to the free 
acids, the potassium salts proved stable to long-term storage.  The methoxy and fluoro 
substituents of 7a and 7b were incorporated to mimic the phenol of the natural substrate 
L-tyrosine.  The synthesis of an epoxide, where R=OH was not feasible as the final 
product is not stable.  Regardless, the methoxy and fluoro- substituents provide valid 
probes for the interactions of the natural phenolic hydroxyl group with the active site of 
TAM.  
  
3.4 Inhibition Studies of the Substrate Analogs of SgTAM 
 Binding of the designed inhibitors (7a-c and 8a-c) was evaluated by 
determination of their inhibition constants (IC50) with SgTAM. To determine these 
values, the natural substrate, L-tyrosine, was incubated with the enzyme and various 
concentrations of analogs. The inhibitory efficiency was measured using an HPLC-based 
assay employing ortho-phthaldialdehyde (OPA) derivatization of the starting L-tyrosine 
and product (S)--tyrosine.4 The results (Figure 3) show all analogs inhibit the reaction in 
14a R=H
14b R=OMe
14c R=F
R
CO2Et
O
15a R=H
15b R=OMe
15c R=F
7a, R=H
7b, R=OMe
7c, R=F
b
(41%, 99%ee)
(28%, 86%ee)
(37%, 97%ee)
R
CO2Et
R
CO2
-
O
a
(70%)
(62%)
(41%)
 
 
Scheme 2. Synthesis of epoxide-based inhibitors of SgTAM.  Reagents and conditions: (a) 30 mol% Shi's epoxidation catalyst, 
oxone, NaHCO3, Na2EDTA, cat. TBAHS, H2O-CH3CN. (b) KOH, MeOH.  Isolated yields and percent enantiomeric excess 
are indicated. 
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a concentration-dependent manner and reveal that the designed substitutions are tolerated 
by the enzyme.   To observe adequate turnover in the HPLC assay, a high concentration 
(0.5 mg/mL) of enzyme and substrate L-tyrosine (75 μM) was necessary, resulting in IC50 
values in the mM range.  These compounds are not ideal inhibitors of the enzymatic 
system, but as mechanistic probes they were believed to bind well enough to TAM to be 
observed in the active site.  
 
3.5 Crystallization of SgTAM in the Presence of Substrate Analogs  
 Co-crystals of 7 and 8 with SgTAM were prepared by incubation of the analogs 
with the enzyme for 1 hour at room temperature followed by crystallization under 
conditions similar to that reported for the native structure.
8
 Crystals formed within 48 
hours, but were allowed to grow for one week before being harvested, frozen in a cryo-
protectant solution and screened.  The crystal morphology tended to be less like needles 
than native SgTAM, and the crystals formed as large rectangular prisms.  
 
Figure 3. IC50 measurements for synthetic inhibitors of SgTAM.  Experiments were done in 
triplicate and a representative graph is illustrated. 
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 The co-complex structure was solved using molecular replacement from the 
native structure of SgTAM and refined to 2.0Å resolution whereas native crystals were 
resolved at 2.5Å.  As with the native structure, the solution for each structure was solved 
in the space group P21212.  The X-ray crystal structures of 8a, 8b and 7b bound to 
SgTAM provided a structural basis for recognition of the natural substrates and for the 
overall reaction mechanism. 
 
3.6 Overall Structures of SgTAM bound to Analogs 
 Overall, the structures of the SgTAM co-complexes were very similar to the 
unliganded enzyme, with no significant structural variations (R.M.S.D. over all atoms = 
0.71Å).  The active site residues were in the same positions, and the active site loops 
were still well defined in each structure.  
 
3.7 Structures of Product Analogs Covalently Bound to MIO 
 Although the overall structures of inhibitor bound TAM are similar, continuous 
electron density corresponding to 8a covalently bound to MIO was observed (Figure 4A). 
Multiple conformations and binding possibilities for the inhibitor were evaluated 
focusing on adducts predicted by the two mechanisms shown in Figure 1.  Only the 
amine bound adduct (corresponding to path A) fit the density and the resulting complex 
was fully refined using simulated annealing and energy minimization. The observed 
density does not match an MIO/phenyl ring adduct consistent with a Friedel-Crafts 
mechanism and the final model places the MIO methylene carbon 3.4 Å from the meta-
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carbon of the tyrosine ring. In addition, the observed binding mode is consistent with the 
structure of an amino/phosphonate inhibitor (AIP) bound to tyrosine ammonia lyase.
11
 
 The structure provides detailed insight into the chemistry of the reversible 2,3 
amino shift catalyzed by SgTAM. The key substrate specificity determinants for the 
amino acid are His93 and Tyr415.  These two residues form a bifurcated hydrogen bond 
with the substrate phenol (Figure 4B). The residue corresponding to His93 has been 
implicated as a key specificity determinant in tyrosine and phenylalanine ammonia 
lyases.
11, 16
 The carboxylate of the substrate also forms hydrogen bonds with Arg311 and 
Asn205.   
 Overall, the active site contains a high percentage of aromatic residues. The MIO 
is stacked with Phe356 (not illustrated) and Tyr308 is adjacent to the methylene of the 
MIO.  Tyr63 is positioned in close proximity to the  and -carbons of the inhibitor and 
is well positioned to assist in the elimination chemistry.  Gly70 forms a hydrogen bond 
with the phenol of Tyr63 and both residues are conserved in all MIO-based lyases and 
mutases.  Tyr63 and Gly70 reside on a loop that is often disordered in unliganded 
Figure 4. Structure of SgTAM bound to the substrate analog 8a. A. Electron density map (2Fo-Fc at 
1.5) showing the active site region.  The inhibitor is shown in black and the MIO cofactor red.  B. 
Representation of the major interactions and conformation of the enzyme with the bound analog.  C. 
View of the active site showing the electron density map (Fo-Fc at 2.0) calculated from co-crystals of 
analog 8b showing the position of the methyl group. 
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ammonia lyase crystal structures.  The phenolic oxygen of Tyr63 is positioned 3.2 Å 
away from the -carbon and 3.4 Å from the -carbon of the bound inhibitor.  Tyr63, in 
 
Figure 5. X-ray crystal structures of representative inhibitors bound in the active site of the 
aminomutase SgTAM.   The inhibitors (dark grey), active site amino acid residues (light grey) and 
MIO prosthetic group (dark red) are illustrated as sticks. 
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the phenolate state, can act as a general base, shuttling the proton between the - and - 
positions.   
 The pKa of Tyr63 needs to be lowered in the active site of SgTAM to favor the 
anionic form.  Two aspects are evident from the X-ray structure that contribute to a lower 
pKa: i) stabilization of the negative charge by the hydrogen bond to Gly70 and ii) the 
significant number of -helices with positive dipoles pointed at the active site.  Also 
consistent with this mechanism, the measured optimal pH for SgTAM is ~9.
4
 To confirm 
the importance of Tyr63 in the reaction mechanism, site-directed mutagenesis was used 
to remove the phenol by substituting phenylalanine. The resulting mutant, Y63F, had no 
measurable aminomutase activity even at high substrate concentrations and over extended 
reaction times. 
  
3.8 Epoxide Analogs Bound to SgTAM 
 Next, the structure of the epoxide analog 7b bound to TAM confirms that the 
analog forms a covalent interaction with the electrophilic MIO through the epoxide 
oxygen.  Electron density for a -hydroxyl is clear in the electron density maps, 
corresponding to the addition of water as illustrated in Figure 2. The binding mode of 7b 
is analogous to that predicted for amine adducts with MIO-based enzymes. The presence 
of the 4-fluoro group in 7b pushes the aryl ring slightly away from the recognition 
elements His93 and Tyr415 (Figure 5).  These residues are predicted to form hydrogen 
bonds with the substrate 4-hydroxyl.
11, 16
 The 2,3-diol observed in the crystal structure 
appears to be a single diastereomer (2R, 3S) and results from attack and inversion at the 
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3-position of 7. To provide evidence that the ring opening is enzyme catalyzed, 7c was 
incubated under standard assay conditions with and without SgTAM and analyzed by 
high-resolution mass spectrometry.  Substrate analog 7c was converted to the 
corresponding diol when incubated in the presence of SgTAM, but was recovered intact 
after a 24 incubation in buffer without enzyme.  Therefore, the hydrolysis of the epoxide 
ring was considered to be enzyme catalyzed as shown in Figure 2.  The observed diol can 
be generated either through an SN1 (as shown) or SN2-type mechanism.  The result is a 
structure that is a close mimic of the starting adduct between L-tyrosine and MIO. 
 To further confirm the position of 7b and 8a in the active site, ,-difluoro--(S)-
4-methoxyphenylalanine 8b was prepared and its co-crystal structure was determined.   
The difference map (Fo-Fc) of the methoxy adduct with the final model of 8a (Figure 4C, 
green density) established the position of the methyl group of 8b as consistent with our 
assignment (Figure 5).  The methyl group is accommodated in the active site by 
displacing an ordered water molecule (Figure 4A).   
 
3.9 Mechanistic Conclusions of MIO Dependent Enzymes 
 Presented above, is the solution of three crystal structures of SgTAM bound to 
mechanistic probes.  Two were based on product-like structures and one substrate-like 
and together provide a detailed picture of catalysis of MIO-dependent aminomutases.  
We were able to visualize binding to the active site MIO as well as variations in the 
chemical structures of the small molecule probes, which allowed us to obtain an 
understanding of recognition elements involved in substrate binding.  In each case, 
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density was observed that was consistent with a mechanism involving amine activation 
by MIO (path A in Figure 1).  This represents the first conclusive structural evidence 
favoring one mechanism over the other.   
 The variations of the para-position on the aromatic ring of the probes gave us an 
idea of substrate recognition as well.  Previously, in ammonia lyase (HAL and PAL) 
studies the residue corresponding to His93 was shown to act as a substrate recognition 
element.
16
 Our structures proved that this residue is important for substrate recognition, 
and illustrated an important hydrogen bond between the imidazole of His93 with the 
substrate phenol.   One difference between the lyases that had previously been shown in 
the native structure of SgTAM, was the presence of Tyr415.  These structures showed 
that this residue also interacted directly with the phenol of the substrate. Perhaps the 
interaction between the substrate and this residue results in tighter binding, which would 
result in the 2,3-amino shift instead of the release of the ,-unsaturated acid from the 
active site.  
 The reaction of the related phenylalanine aminomutase from Taxus has been 
shown to proceed through stereospecific exchange of the proS hydrogen.
17
 L-Tyr bound 
to MIO in a trans-configuration places the proS hydrogen in proximity to Tyr63 and anti-
periplanar to the ammonium leaving group. The stereochemistry of the reverse reaction 
of aminomutases (Tyr to Tyr) is variable.  SgTAM catalyzes the racemization 
of (S)-Tyr and a highly homologous tyrosine aminomutase from chondramide 
biosynthesis produces the opposite stereochemistry at the -position, (R)--Tyr from L-
Tyr.
7
 The stereochemical differentation can occur from rotation of the trans-cinnamate 
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intermediate to present the opposite face to the amine-MIO adduct.  Modeling of this 
orientation shows the active site can accommodate this change while still maintaining 
binding interactions between Arg311, His93 and Tyr415. 
  
 
Figure 6. The mechanism of the MIO-based  aminomutase SgTAM.  The overall reaction [L-tyrosine 
to (S)--tyrosine] is boxed.  The MIO prosthetic group is derived from the protein backbone and shown 
abbreviated. 
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3.10 Conclusions and Future Directions 
 The presented structures of the aminomutase SgTAM provide strong evidence that 
MIO-based enzymes use covalent catalysis through the -amine of the substrate to direct 
chemistry (Figure 6).  For ammonia lyases, a covalent adduct orients both an enzymatic 
base and the leaving group in an ideal orientation for an E2-type elimination.  For 
enzymes with aminomutase activity, the conjugate 1,4-addition into the relatively non-
electrophilic 4-hydroxycinnamate is facilitated by orienting the amino-bound 
intermediate and maintaining the nucleophile in the neutral form.  Differentiation of the 
two catalytic pathways can be accomplished by retention of ammonia in the closed active 
site of aminomutases as well as a more tightly bound ,-unsaturated intermediate.8 
 Future studies will attempt to visualize L-tyrosine and (S)--tyrosine in the active 
site of SgTAM.  This is expected to occur by mutation of mechanistically vital amino 
acid side chains like Tyr63.  With the enzymatic base not present in the active site, 
binding should occur to the natural substrate without the forward or reverse reaction 
proceeding past the initial addition into MIO.   
 Further mutational studies will be done to relax the substrate specificity of this 
system, and to attempt to increase the catalytic efficiency of SgTAM.  This would be 
advantageous in a chemoenzymatic sense.  It should also be determined if substrate 
analogs could be incorporated into the natural product scaffold of C-1027.  An increased 
knowledge of biosynthetic pathways should facilitate efforts towards protein 
engineering.
18
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Materials and Methods 
 
General. Infrared spectra (IR) were recorded on a Perkin Elmir 781 spectrophotometer, 
max in cm-1. Bands are characterized as broad (br), strong (s), medium (m), and weak (w). 
1H NMR spectra were recorded using a Varian Unity INOVA 400 MHz (400 MHz) 
spectrometer. Chemical shifts are reported in ppm from trimethylsilane with the solvent 
as the internal standard (CDCl3:  7.26 ppm, DMSO-d6:  2.50 ppm, CD3OD: 
 4.87 ppm). Data are reported as follows: chemical shift, (multiplicity [singlet (s), 
doublet (d), triplet (t), quartet (q), doublet of doublets (dd), triplet of doublets (td), and 
multiplet (m))], coupling constants [Hz], and integration. 13C NMR spectra were 
recorded on a Varian Unity INOVA 400 MHz (100 MHz) spectrometer with complete 
proton decoupling. Chemical shifts are reported with the solvent as the internal standard 
(CDCl3:  77.23 ppm, DMSO-d6:  39.51 ppm, CD3OD:  49.15 ppm) 19F NMR spectra 
were recorded on a Varian Unity INOVA 400 MHz (376 MHz) using trifluoroacetic acid 
as an internal standard ( -76.55 ppm). High resolution mass spectrometry (MS) was 
performed at the Mass Spectrometry Facility at Boston College on a LCT ESI-MS. 
Diastereomeric ratios were determined using chiral HPLC analysis (Chiral Technologies 
Chiralpak AD column (0.46 cm x 25 cm). Optical rotations were measured on a Rudolph 
Research Analytical Autopol IV Polarimeter.  
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 Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
Unless otherwise stated all reactions were performed in flame-dried glassware under an 
atmosphere of N2 and were ran in solvents dried and purified using stills from Glass 
Contour (Santa Monica, CA). Deuterated NMR solvents were purchased from Cambridge 
Isotope (Andover, MA). Purification of intermediates was performed on silica gel 60 
from VWR (West Chester, PA). All work-up and purification procedures were performed 
in air using solvents purchased from Fisher Scientific (Pittsburgh, PA). All previously 
synthesized compounds made in our lab match published spectra.  
 For the Reformatsky chemistry, zinc was activated prior to use as follows: The 
required amount of zinc was added to 6 N HCl and was slowly stirred until bubbling of 
the solvent ceased. The zinc was then collected by vacuum filtration, washed 3 times with 
distilled water, three times with acetone, and three times with diethyl ether. Clumps of 
zinc were broken up, and the activated zinc was dried overnight under vacuum. For all 
other reactions, chemicals were used as received from the manufacturer. 
 
Enzyme Production.  SgTAM was cloned into the pET28a vector with NdeI and HindIII 
sites (generous gift from B. Shen, U. Wisconsin, Madison).  The vector was transformed 
into BL21(DE3) cells and grown in LB media at 37 ˚C until cell density reached 
O.D.=0.6.  Overexpression was induced by adding IPTG (50 μM), followed by overnight 
incubation at 18
 
˚C.  Cells were pelleted with centrifugation and lysed using a French 
Press cell disruption system.  The enzyme was then purified with Ni-NTA affinity resin 
(Qiagen), followed by cleavage of the hexa-histidine tag with the protease thrombin (2 
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days at 4
 
˚C).  Further purification was performed with a HiTrap-Q ion exchange 
followed by a HiLoad 16/60 SuperDex 200 gel filtration column (GE Biosciences). 
 
Crystallization and Data Collection. SgTAM (58 kDa, 539 amino acids) from 
Streptomyces globisporus (Locus AY048670) was crystallized in the presence of the 
inhibitors by the hanging drop vapor diffusion method at 20 ˚C.  SgTAM (1.5 μL of 20 
mg/mL in 50 mM CHES and 50 mM KCl, pH 9.0) was mixed 1:1 with 2.5 mM stock 
solutions of inhibitor (50 mM CHES and 50 mM KCl, pH 9.0). This was allowed to 
incubate at room temperature for 1 hr before 1.5 μL of the solution was mixed with 1.5 
μL of reservoir solution (4.2 M sodium formate, 100 mM TMAO).  Needle like crystals 
appeared within two days and were allowed to continue growth for several additional 
days.  Crystals were transferred to a cryoprotectant solution of the reservoir solution with 
20% glycerol and briefly soaked before being flash frozen in liquid nitrogen.  X-ray 
diffraction data was collected on the X26C beamline at the National Synchrotron Light 
Source at Brookhaven National Labs on an ADSC Quantum 4 CCD detector. The data set 
was collected at 100 K. Diffraction intensities were indexed, integrated, and scaled with 
HKL2000 as summarized in Table 1. The crystals belongs to the space group P21212, 
with unit cell dimensions: (11) a=92.4, b=145.9, c=75.0 and a=b== 90˚; (8b) a=92.5, 
b=146.3, c=75.0  (7b) a=92.2, b=145.6, c=75.1. 
 
Model Building, Refinement, and Graphics.  The structures were obtained by simple 
molecular replacement with the native structure of SgTAM (PDB code: 2OHY). 
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Refinement cycles and generation of 2Fo-Fc and Fo-Fc maps were done using the CNS 
suite of programs. Cycles of rigid body refinement, simulated annealing, composite omit 
maps, and the addition of waters into the structure were done until Rfree values were no 
longer improving to any extent. To generate images of the structures, the program Pymol 
was used.  
 
Generation of SgTAM Y63F Mutation. The Y63F mutation was introduced into the 
active site by the Quikchange site-directed mutagenesis protocol. (Strategene) The Y63F 
mutation was introduced with the following primer pair: 5- cag aac atc ccc atc ttc ggg gtg 
acc acc ggg-3 and 3-ccc ggt ggt cac ccc gaa gat ggg gat gtt ctg-5 (with the Y63F mutant 
underlined). Several modifications to the Quikchange protocol were made to successfully 
generate mutations to SgTAM. Reaction mixtures consisted of the following: 100 ng of 
template DNA, 500 ng of each primer, 200 μM dNTPs, 5% (v/v) DMSO, 1x buffer, and 1 
unit of Pfu polymerase in a final volume of 100 μL. The PCR program was the following: 
initial denaturing at 95 ˚C for 5 min, followed by 35 cycles at 95 ˚C for 30 s, 62 ˚C for 45 
s, and 72 ˚C for 10 min, and completed by an additional 10 min at 72 ˚C. Following the 
PCR, 20 units of DpnI was added directly into the reaction and incubated at 37 ˚C for 2 
hr. The entire digested reaction mixture was cleaned using a Qiagen PCR purification kit 
and then cyclized overnight by the addition of 400 units of T4 DNA ligase at 16 ˚C. The 
reaction mixture was transformed into NovaBlue Singles (Novagen). The Y63F mutant 
was confirmed by sequencing the full SgTAM coding region. Following sequence 
confirmation, the Y63F construct was transformed into BL21 (DE3).  
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HPLC Assay of Y63F Mutate of SgTAM. Enzyme was obtained in the same manner as 
above. Upon Ni purification, the enzyme was dialyzed into 50 mM CHES and 50 mM 
KCl, pH 9.0. The Y63F mutant was then brought to a final concentration of 5 mg/mL. 
Reactions were run on a 100 μL scale with 0.5 mg/mL of Y63F enzyme and varying 
concentrations of L-Tyrosine. All solutions were kept constant at 50 mM CHES and 50 
mM KCl, pH 9.0. The enzyme was mixed with buffer and allowed to sit at 25 ˚C for 5 
min. The reaction was then initiated by the addition of L-Tyrosine. The reactions were 
incubated at 25 ˚C before quenching with the addition of 10 μL of 200 mM HCl. The 
reaction was then brought back to a pH of 9.0 by the addition of 10 μL of 250 mM 
NaOH. L-Tyrosine and -Tyrosine were then derivatized with 10 uL of a freshly 
degassed ortho-phthaldialdehyde (OPA) solution (8 mg OPA, 100 μL MeOH, 22 μL 
ME, and 8.5 mL of sodium borate buffer pH 10.4). The derivation was quenched after 1 
min by the addition of 1.2 uL of glacial acetic acid. HPLC analysis was then done on 100 
uL of the resulting solution.  
 
Synthesis of Inhibitors. The synthesis of SgTAM inhibitors utilized chemistry 
developed  by Nakata, Ball, and  and Soloshonok with minor modifications.12, 13, 19 The 
syntheses and characterization of compounds 7(a-c) and 8(a-c) were performed by 
Timothy J. Montavon.20, 21  
 
 102 
Determination of IC50. All reactions were performed at 25 °C and were repeated in 
triplicate. Reactions were performed on a 100 uL scale and consisted of 0.5 mg/mL 
enzyme, 0 – 4.65 mM inhibitor, and 75 μM L-tyrosine in an aqueous solution buffered to 
pH 9.0 with 50 mM CHES and 50 mM KCl. The enzyme and inhibitor were incubated 
for 10 min prior to the addition of L-tyrosine and reactions were quenched after 2.5 
minutes by addition of 10 μL of 200 mM HCl until pH 2.0 was reached. The enzyme was 
precipitated by centrifugation at 10,000 RPM for 2 min and the supernatant was returned 
to pH 9.0 by addition of 10 μL of 250 mM NaOH. L-tyrosine and -tyrosine were then 
derivatized with 10 uL of OPA reagent (8 mg OPA, 100 ul MeOH, 22 uL ME, and 8.5 
mL of sodium borate buffer pH 10.4). The derivation was quenched after 1 minute by the 
addition of 1.4 uL of glacial acetic acid and 100 uL of the resulting solution was analyzed 
by HPLC. 
 
CO2
O
H
H
7c
SgTAM
H2O CO2
HO
OH
7c-diol  
 
Enzymatic Conversion of Epoxide 7c to the diol: A 100 μL reaction containing 1.5 
mM of (+)-potassium (2S,3R)-3-phenyloxirane-2-carboxylate and 0.5 mg/mL enzyme 
was run for 24 hours at 25 °C in an aqueous solution buffered to pH 9.0 with 50 mM 
CHES and 50 mM KCl. The reaction was quenched by addition of 10 μL of 200 mM HCl 
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and the mixture was extracted with 500 μL of ethyl acetate. The organic layer was 
collected, dried with MgSO4, and submitted for MS analysis. HRMS (ESI
-) m/z 
calculated for (C9H9O4)
-  182.05 found 182.05. A control was run as above in the absence 
of enzyme. No peak corresponding to the diol could be observed by MS in the control 
reaction. 
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Table 1. Data Collection and Refinement Statistics for SgTAM Bound to 
Substrate Mimics 
 8a 8b 7b 
Crystal Form 
Primitive 
Orthorhombic 
Primitive 
Orthorhombic 
Primitive 
Orthorhombic 
PDB code 2QVE 2RJS 2RJR 
Beam Line NSLS X26C NSLS X26C NSLS X26C 
Wavelength (Å) 1.00 1.00 1.00 
Space Group P21212 P21212 P21212 
Cell Dimensions (Å) 
92.435, 
145.863, 
75.048 
92.494, 
146.286, 
75.009 
92.245, 145.648, 
75.114 
Resolution of 
Structure(Å) 
25.0-2.00 
(2.07-2.00) 
25.0-2.40 
(2.49-2.40) 
25.0-2.10 (2.18-
2.10) 
Unique Reflections 69074 (6758) 40450(3992) 59059(5800) 
Completeness 99.8 (99.1) 99.9(100.0) 98.8(99.1) 
Redundancy 4.7 (3.9) 5.5(4.9) 5.6(5.3) 
I/Sigma(I) 23.2 (3.1) 27.7(4.1) 28.9(6.9) 
Rmerge (%) 9.7 (66.8) 9.2(47.9) 17.2(40.7) 
Monomers per 
Asymmetric Unit 2 2 2 
Solvent Content (%) 40.39 40.39 40.39 
Amino Acid Residues 1056 1056 1056 
No. of Non-hydrogen 
atoms 8044 8451 8501 
Water Molecules 452 398 473 
Rwork/Rfree 0.194/0.224 0.182/0.246 0.1726/0.2116 
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4.1 Introduction 
 Nonribosomal peptide natural products are biosynthesized by large enzymatic 
machinery termed nonribosomal peptide synthetases (NRPSs).
1
 These large enzymatic 
systems take amino acid building blocks and create a wide range of molecular diversity.  
Such compounds include antibiotics
2
, immunosuppressants
3
, and anticancer compounds.
4
 
These large NRPS systems are organized into modules responsible for the chemical 
manipulations of each building block.  Minimally, each module is responsible for 
recognition and activation of a building block (adenylation domain, A-domain); the 
installation of this activated amino acid on to a carrier protein (peptidyl carrier protein, 
PCP-domain); and an elongation domain which is responsible for catalyzing the 
formation of a peptide bond between the activated acid of the upstream 
aminoacyl/peptidyl-S-PCP and the free amino group of a downstream aminoacyl-S-PCP 
(Figure 1).
1
 Numerous chemical modifications can subsequently be made to the building 
blocks.  Enzymes for oxidation, methylation, epimerization, and cyclization result in 
large structural diversity. 
 Many important drugs are derived from natural products.  The use of novel NRP 
analogs could lead to the development of novel drugs with improved activity, 
bioavailability, and less resistance.
5
 Practical access to a library of natural product 
derivatives are not easy to come across. Many of these compounds require very long 
synthetic routes that would be cost prohibitive for testing analogs and large-scale 
production.
6
 One way to circumvent this problem may be to incorporate engineered 
NRPS enzymes into bacteria to create libraries of natural product analogs (combinatorial 
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biosynthesis).
5
 One potential method to engineer NRP biosynthetic pathways is to 
generate A-domains with altered specificity to incorporate different amino acids into 
natural product scaffolds. For this technology to be of general use, a detailed 
understanding of A-domain structure and molecular recognition will be required.  
Figure 1 The chemistry of a minimal Nonribosomal peptide synthetase.  An amino acid is activated 
by the adenylation domain with ATP, and loaded onto the peptidyl carrier protein (PCP).  The 
condensation domain catalyzes the amide bond formation between a downfield amine and the upfield 
thioester.  The activated amino acid is attached to the PCP domain by a phosphopantetheine arm 
which attacks the aminoacyl adenylate species shown.  
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 A limited number of X-ray structures have been solved for A-domains.
7-9
 With 
the first 3-dimensional structure of the A-domain, a proposal of a rational and predictable 
code for amino acid recognition was conceived.
10, 11
 This code combines structure and 
sequence data and exploits similarities between all A-domains.  Using this approach, 
Townsend and coworkers were able to predict the substrate specificity of A-domains 
from their gene sequence.
11
 A major problem with this code is that while amino acids wih 
polar and aromatic side chains can be accurately predicted, it remains a challenge to 
explain how small hydrophobic side chains are recognized.  With a recent structure of the 
D-alanine A-domain from lipoteichoic acid biosynthesis,
9
 more information has been 
gained concerning this problem.  
 
4.2 Leinamycin 
 Leinamycin is a structurally complex natural product with mechanistically 
interesting and potent antitumor/antibiotic activity.
12
 It demonstrates antibiotic activity 
against both gram-positive and gram-negative bacteria.  This natural product was isolated 
by Nakano and coworkers from the soil bacteria Streptomyces atroolivaceus in Japan in 
1989.
13
 After structural determination, an elegant total synthesis by Fukyama
14
 confirmed 
the assignment.  The results revealed an architectural feature not found in any other 
natural product known to date.  This unsual moiety is a 1,3-dioxo-1,2-dithiolane ring 
system which provides leinamycin with multiple ways in which it can cause cell death 
upon entering a target cell (Figure 2).
15
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 Leinamycin biosynthesis is 
initiated by a stand-alone A-domain 
(LnmQ) that is specific for activating D-
alanine with ATP to form an active 
aminoacyl adenylate species with the 
release of pyrophosphate.
16
 Being a 
stand alone domain and the first domain 
in the biosynthetic machinery, it is an 
ideal target for manipulation of the 
natural product scaffold.  The position of the D-Ala is distant from the active 1,3-dioxo-
1,2-dithiolane ring, suggesting that augmentation of this position could produce structural 
analogs without being detrimental to biological activity (Figure 2).   
 To understand the role of LnmQ in initiating leinamycin biosynthesis, 
biochemical and crystallographic studies were undertaken.  The following discussion is a 
description of our efforts toward a full characterization of this enzyme.  
 
4.3 Cloning of LnmQ, a D-Ala Specific A-Domain 
 The lnmQ gene was amplified from the genomic DNA of Streptomyces 
atroolivaceus by polymerase chain reaction (PCR) and cloned into the T7 overexpression 
system vector pET37b by Shen and coworkers.
16
 The pET37b construct encodes for a 
non-cleavable C-terminal His8-tagged protein when overproduced in E. coli. Results from 
multiple rounds of high-throughput crystal screening suggested that a cleavable histidine 
 
Figure 2. The structure of Leinamycin from 
Streptomyces atroolivaceus.  The location of the D-
Ala is highlighted.  
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tag would facilitate better crystal growth.  Therefore, we subcloned the lnmQ gene into 
the pET30a vector (Figure 3A), which yielded an N-terminal His6-tagged protein with an 
enterokinase cleavage site.  This enabled the removal of the histidine tag by the 
proteolysis after the initial isolation of the protein. The subcloning protocol was 
accomplished by cleaving the DNA out of the pET37b construct with restriction 
 
Figure 3. LnmQ was subcloned to pET30a overexpression vector. (A) The cleavage of LnmQ in 
pET30a to show the gene insert. (B) LnmQ prior to and after enterokinase cleavage. (C) Pure LnmQ 
after chromatography. 
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endonucleases and subsequent ligation of the lnmQ gene product into the pET30a 
construct.   
 
4.4 Isolation and Purification of LnmQ 
 With the proper construct in hand, we overproduced LnmQ by transforming the 
pET30a overexpression vector of LnmQ into BL21 (DE3) E. coli cells.  These cells were 
grown and induced to produce protein by the addition of isopropyl thiogalactoside 
(IPTG).  After induction and overnight expression at 18 
o
C, the cells were pelleted and 
lysed to harvest the protein.   
 The lysate was clarified by centrifugation and the resulting supernatant was 
incubated with Ni-NTA resin, which specifically binds to histidine-tagged proteins.   
After washing the resin, elution with a high concentration of imidazole (250 mM) gave 
relatively pure protein.  The histidine tag was then removed by proteolytic cleavage with 
enterokinase, (Figure 3B) and the resulting LnmQ protein was purified by both anion 
exchange and size exclusion chromatography (Figure 3C).  
 Structural investigations of LnmQ began by screening multiple crystallization 
conditions using a commercially available sparse-matrix screen.  Starbursts of crystals 
were found to form in conditions with polyethylene glycol (10K) as a precipitant and 
mopholineethanesulfonic acid (MES) buffered to pH 6.0.  These conditions were 
investigated, and the addition of sodium chloride and glycerol were shown to stabilize 
crystal formation.  Even though glycerol and salt aided in crystallization, the morphology 
of LnmQ crystals was unchanged, and the resulting small starbursts did not give quality 
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diffraction data.  Further studies involved the investigation of buffer, precipitants and 
stabilizing compounds on crystallization. However, no improvement in morphology was 
obtained.  
 
4.5 Selenomethionine preps of LnmQ 
 Investigation into the formation of selenomethionine LnmQ was done to see if 
 
Figure 4. (A) Purified LnmQ after the incorporation of Se-Met residues. (B) The structure of 
Se-Met. (C) Starburst crystals of LnmQ Se-Met. 
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diffraction quality crystals could be formed, thus solving the structure and the phase 
problem all at once.  With diffraction quality Se-Met crystals in hand, diffraction data 
collected at a synchrotron X-ray source would facilitate the solution of the phases.
17
 Data 
toward a structure solution is obtained by measuring the diffraction of X-ray radiation 
through a crystal lattice.  This data, because it represents a wave function, is made up of 
three parts; the frequency, the amplitude, and the phase.  The frequency is known from 
the X-ray source and the amplitude is the square root of the intensity as measured on a 
detector.  This leaves the phase as the variable to be determined.  There are several ways 
in which to solve the phase problem.  This can be done by molecular replacement, as we 
utilized for the solution of SgTAM.  There is also, multi-wavelength anomalous 
dispersion (MAD), which is a technique that relies on the known position of a small 
number of atoms in the structure to estimate the phases for all the atoms.
18
  
 The strategy of incorporating selenium in place of the sulfur atom in methionine 
has been shown to be a facile approach for MAD phasing techniques.  Anomalous 
dispersion results because atoms both absorb and emit radiation.  When the wavelength 
of the radiation is just below an atom’s characteristic emission wavelength, absorption 
drops suddenly.  This change as a function of wavelength is called the ‘absorption edge’.  
Light atoms, like those found in proteins (carbon, nitrogen, oxygen, etc.) have an 
absorption edge that is higher in energy than that used for atomic resolution structure 
solutions (X-rays, ~1Å wavelengths).  However, heavier atoms, like selenium, have their 
absorption edge in the range of X-ray radiation.  This allows one to obtain data at a 
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synchrotron where tuning specific wavelengths is possible, facilitating the gathering of 
anomalous data.   
 LnmQ was grown in minimal media with the addition of the amino acid Se-Met, 
and the resulting protein was harvested and purified (Figure 4).  Initially, crystal screens 
were repeated to determine if Se-Met derivatized LnmQ behaved similarly to the native 
protein.  The crystal hits obtained were identical to native LnmQ; therefore, 
investigations toward the crystallization conditions with polyethylene glycol of varying 
size, MES, NaCl, and glycerol were screened to optimize crystal morphology.  In these 
studies, crystals were formed with the same starburst morphology as before, but had 
larger needles.  This result was promising initially, but the subsequent X-ray diffraction 
data of several needles showed a decrease in quality, or no diffraction at all.  At this 
point, a new direction needed to be investigated to obtain diffraction quality crystals. One 
approach that can improve the quality of crystals involves using substrate analogs or 
inhibitors that bind to an enzyme and stabilize its overall conformation. 
 
4.6 Substrate and Substrate Analog Studies with LnmQ 
 The A-domains that had been structurally characterized by X-ray crystallography 
all contained small molecules in their active sites.
8, 9
 For PheA, the A-domain from 
gramicidin biosynthesis, binding was shown with AMP and phenylalanine.  In the case of 
DltA from lipoteichoic acid, the crystallization conditions had ATP, and D-Ala, but only 
density for AMP was observed in the active site.  With these results in mind, trays for 
LnmQ were set up with combinations of ATP, AMP, MgCl2, and D-Ala.  Unfortunately, 
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crystals were not obtained and only precipitated protein was observed under all 
conditions tested.   
 In addition to the above experiments, we decided to attempt crystallization in the 
presence of a stable, product-like analog.  Studies had been done for the synthesis of 
inhibitors of related systems.
19
 Non-hydrolysable mimics of the aminoacyl adenylate 
species had been made, and shown to inhibit adenylation domains.  We synthesized a D-
Ala-sulfamoyl adenosine compound previously made by May et al., for the study of 
DltA.
19
 The synthesis of this molecule (6) is shown in Scheme 1.  
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Scheme 1.  The synthetic scheme of the sulfamoyl adenosine inhibitor for LnmQ. (a.) 2,2-
dimethoxypropane, PTSA, Acetone (b.) 1. 1,2-dimethoxyethane, NaH 2. sulfamoyl chloride (c.) Boc-D-
Ala, DCC, HOBt, DBU, DMF (d.) 1N HCl in 1:1 THF/H2O 
 Briefly, following acetonide protection of adenosine (1), incorporation of 
sulfamoyl chloride (3) gave sulfamoyl adenosine (4).  Amide bond coupling was 
accomploished using relatively long reaction times due to the non-nucleophilic nature of 
the free amine of 4.  A global deprotection of 5 gave the final product (6) in modest 
overall yields.  Purification of the desired compound was done with multiple rounds of 
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preparatory HPLC.  After obtaining this compound in sufficient quantities, we 
commenced screening with LnmQ for crystallization conditions.  Unfortunately, 
obtaining diffraction quality crystals was not initially accomplished, and work is 
continuing to optimize our initial crystal hits to obtain diffraction quality data and a 
structure. 
 
4.7 Conclusions and Future Work 
 The structure of LnmQ remains unsolved. Questions concerning the activation 
and recognition of small, hydrophobic amino acids in NRPS biosynthetic pathways 
remain unanswered. 
9
 A structure of LnmQ bound with the D-Ala sulfamoyl adenosine 
inhibitor would give information about the recognition of small amino acid side chains 
and increase our ability to engineering the active site of LnmQ to accept new substrates.   
 Pyrophosphate exchange assays have been done with LnmQ
16
 and preliminary 
results show that the sulfamoyl adenosine 6 is able to inhibit the activity of LnmQ.  More 
crystal screening could facilitate the growth of diffraction quality crystals.  In the mean 
time, it might be advantageous to utilize biochemical techniques such as error-prone PCR 
in an attempt to change of the selectivity of LnmQ.  If relaxed substrate specificity could 
be obtained for LnmQ, it would be intriguing to make analogs of leinamycin and test the 
biological activity of these compounds.  
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Materials and Methods 
 
General   
 For general laboratory materials and instrumentation see Chapter 3. 
 
Enzyme production   
 LnmQ (55 kDa, 516 amino acids) from Streptomyces atroolivaceus was sub-
cloned into the NcoI and XhoI sites of the pET30a vector, from the LnmQ construct in 
the pET37b vector (generous gift from B. Shen, U. Wisconsin, Madison).  The resulting 
vector was transformed into BL21(DE3) cells and grown in LB media at 37 ˚C until cell 
density reached O.D.=0.6.  Overexpression was induced by adding IPTG to a final 
concentration of 50 μM, followed by overnight incubation at 18 ˚C.  Cells were pelleted 
with centrifugation and lysed using a French Press cell disruption system.  The enzyme 
was then purified with Ni-NTA affinity resin (Qiagen), followed by cleavage of the hexa-
histidine tag with the protease enterokinase (2 days at 4
 
˚C).  Further purification was 
performed with a HiTrap-Q ion exchange followed by a HiLoad 16/60 SuperDex 200 gel 
filtration column (GE Biosciences). 
 
Se-Met preparation of LnmQ 
 For LnmQ production with the incorporation of Se-Met residues, stocks of M9 
minimal media are made.  To one liter of M9 media, 10 mL of 20% glucose solution, 2 
mL of MgSO4 (1 M stock), 50 μL of CaCl2 (2 M stock), 100 μL of a 0.5% Thiamine 
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solution and 40 mg of all the canonical amino acids except, Gly, Ala, Pro, Gln, Asn, Cys, 
Met are added.  One colony of LnmQ in BL21 (DE3) cells is added to the minimal media 
and grow to an O.D.=0.6.  At this point 100 mg each of Thr, Lys, and Phe and 50 mg of 
Leu, Ile, and Val are added followed by 120 mg of D,L-selenomethionine.  Growth is 
continued for 30 minutes at 37 
o
C, cooled to 18 
o
C and overexpression is induced with 
IPTG (50 μM) and shake overnight.   
 
Crystallization of LnmQ  
 Initial crystal hits of LnmQ were obtained by screening with the Hampton Crystal 
Screens I and II (Hampton Research HR2-110 and HR2-112).  Optimization of initial 
conditions was performed by the hanging drop vapor diffusion method at 4 ˚C.  LnmQ 
(1.5 μL of 10 mg/mL in 20 mM Tris-HCl, 1 mM -mercaptoethanol, 100 mM NaCl, and 
10% glycerol, pH 7.5) was mixed with 1.5 μL of reservoir solution (10% PEG 10K, 100 
mM MES pH=6.0, 12% Glycerol, 100mM NaCl).  Starburst crystals appeared within one 
day and were allowed to continue growth for approximately one week to increase the size 
of the crystals.  Crystals were transferred to a cryoprotectant solution of the reservoir 
solution with 20% glycerol and briefly soaked before being flash frozen in liquid 
nitrogen.   
 Crystallization of LnmQ was attempted in the presence of ATP, AMP, MgCl2 and 
D-Ala by the hanging drop vapor diffusion method at 4 ˚C.  LnmQ (1.5 μL of 20 mg/mL 
in 20 mM Tris-HCl, 1 mM -mercaptoethanol ,100 mM NaCl, and 10% glycerol, pH 7.5) 
was mixed 1:1 with varying concentrations of the compounds; stock solutions of the 
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substrates were in (20 mM Tris-HCl, 1 mM -mercaptoethanol ,100 mM NaCl, and 10% 
glycerol, pH 7.5).  The following combinations were attempted: -each of the four 
molecules individually; ATP, MgCl2, and D-Ala; AMP, MgCl2, and D-Ala; ATP and 
MgCl2, AMP and MgCl2, D-Ala and Mg
2+
.  The drops were allowed to incubate at 4 
o
C 
for 1 hr before 1.5 μL of the solution was mixed with 1.5 μL of reservoir solution (10% 
PEG 10K, 100 mM MES pH=6.0, 12% Glycerol, 100mM NaCl). No viable crystals were 
detected.  
 Crystallization of LnmQ was attempted in the presence of the inhibitor (6) by the 
hanging drop vapor diffusion method at 4 ˚C.  LnmQ (1.5 μL of 20 mg/mL in 20 mM 
Tris-HCl, 1 mM -mercaptoethanol ,100 mM NaCl, and 10% glycerol, pH 7.5) was 
mixed 1:1 with 0.05, 0.1, 0.5, 1.0, and 2.5 mM concentrations of inhibitor; stock 
solutions of inhibitor (20 mM Tris-HCl, 1 mM -mercaptoethanol ,100 mM NaCl, and 
10% glycerol, pH 7.5). This was allowed to incubate at 4 
o
C for 1 hr before 1.5 μL of the 
solution was mixed with 1.5 μL of reservoir solution (10% PEG 10K, 100 mM MES 
pH=6.0, 12% Glycerol, 100mM NaCl). No viable crystals were detected.  
 
Synthesis of inhibitors  
 The synthesis of LnmQ inhibitors utilized chemistry developed  by Marahiel and 
coworkers with minor modifications.
19
 The synthesis of (6) was done in collaboration 
with William Hillmann, Eric Dimise, and Geoff Stoker.  
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Synthesis of 2’,3’-O-isopropyliden-adenosine (2)  
 2.014 g (7.4 mmol, 1 eq.) of adenosine (1) was suspended in 100 mL of dry 
acetone in a 250 mL flame-dried round bottom flask stirring under N2.  To this 
suspension was added 18.2 mL (148 mmol, 20 eq.) of 2,2-dimethoxypropane and 2.8 g 
(17.8 mmol, 2 eq.) of p-toluenesulfonic acid.  The reaction was stirred for 30 minutes at 
room temperature as the solid adenosine dissolved and the color changed from white to 
deep amber.  After 30 minutes, neutralization was achieved with the addition of a 
saturated solution of NaHCO3 on ice.  The resulting white precipitate was filtered off, and 
the filtrate was concentrated under reduced pressure.  The residue was diluted with a 3:1 
CHCl3:i-PrOH solution and washed three times with sat. NaHCO3.  The organic layer 
was collected and dried with MgSO4, and the solvent was removed under reduced 
pressure.  Flash silica gel chromatography in a 10:1 CH2Cl2: MeOH, afforded the desired 
product (2) as a white solid (1.7 g, 76% yield).  The spectra and characterization data for 
2 matched published data.
19
 
O N
HO N
N N
NH2
O O
O N
O N
N N
NH2
O O
S
H2N
O
O
1) 1,2-dimethoxyethane, NaH
2)                                 0 oC
S
H2N Cl
O O
2 3 4  
Synthesis of 2’,3’-O-Isopropyliden-5’-O-sulfamoyl adenosine (4) 
 125 
 2.338 g (7.61 mmol, 1 eq.) of (2) was dissolved in ~90 mL 1,2-dimethoxyethane 
in a flame dried 250 mL round-bottommed flask, stirring under N2.  0.67 g (16.74 mmol, 
2.2 eq.) of NaH (60% in mineral oil) was added and vigorous bubbling was observed 
with the evolution of H2 gas.  The reaction was allowed to stirred for two hours and then 
cooled to 0 
o
C on an ice bath.  1 eq. of freshly prepared sulfamoyl chloride
10
 (3) was 
added dropwise.  The reaction was allowed to stir on ice as it melted overnight.  After 12 
hours, the reaction was quenched with the addition of 10 mL of ethanol.  The reaction 
was filtered and the solvent was removed under reduced pressure.  The resulting solid 
was dissolved in 150 mL MeOH, filtered and concentrated again.  Flash silica gel 
chromatography in a 10:1 CH2Cl2: MeOH, afforded the desired product (4) as an off-
white solid (1.68 g, 57% yield). The spectra and characterization data for 4 matched 
published data.
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Synthesis of 2’,3’-O-Isopropylidene-5’-O-[N-(N-tert-butoxycarbonyl-D-alanyl)-
sulfamoyl]-adenosine (5) 
 In a 100 mL flame dried round-bottommed flask 0.72 g (1.86 mmol, 1 eq.) of 4 
was dissolved in 20 mL DMF under N2 with stirring.  The following reagents were added 
sequentially: 0.37 of Boc-D-Ala (1.95 mmol, 1.05 eq.); 0.314 g of HOBt (2.05 mmol, 1.1 
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eq.); and 0.28 mL of DBU (1.86 mmol, 1.5 eq.).  This mixture was cooled on ice, and 
then 1.54 g of DCC (7.45 mmol, 4 eq.) was added.  The reaction was stirred on ice for 
one hour and left at room temperature overnight.  At this time, the organic solvent was 
removed under vacuum.  The resulting residue was water and extracted 4 times with 
DCM.   The organic layer was washed twice with 1 N HCl, once with NaHCO3, and once 
with brine.  The organic layer was concentrated under reduced pressure and dried under 
vacuum overnight.  After drying, the desired product (5) was obtained as an off-white 
solid without further purification (1.68 g, 66% yield).  The spectra and characterization 
data for 5 matched published data.
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Synthesis of 5’-O-[N-(D-alanyl)-sulfamoyl]-adenosine 
 0.68 g (1.23 mmol) of 5 was dissolved in 10 mL of THF in a 50 mL round-
bottommed flask.  This was chilled on an ice bath.  10 mL of 2N HCl was added to the 
flask.  The reaction stirred on ice for 3 hours, at which time the mixture was frozen and 
lyophilized. After purification via preparative RP-HPLC (0.1% TFA in H2O to 100% 
acetonitrile) the spectra and characterization data for 6 matched published data.
19
 Only 
around 25 mg of product was obtained.  
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 Many questions exist in the field of mechanistic enzymology concerning the 
biosynthesis of non-natural amino acids.  We have sought to address two problems; the 
biosynthesis of -amino acids, and the activation and recognition of D-amino acids.   
 Much work has been done in the field of MIO containing enzymes; from 1926 
when Edlbacher began investigating the catabolism of histidine in liver extracts,
1
 to our 
studies of SgTAM bound to mechanistic probes to provide a ‘snapshot’ of the enzymatic 
pathway of MIO dependent aminomutation reactions.
2
 Over the years, labeling studies 
were done with numerous carbon, nitrogen and deuterium labeled substrates.
3
 This class 
of enzymes was also probed with substrate mimics, product mimics, and a wide array of 
inhibitors.
4, 5
 By taking into account all of this information, we were able to propose a 
general mechanism for MIO dependent enzymes.
2
 This electrophilic moiety is only part 
of the solution that enables this class of enzymes to catalyze either the elimination of 
ammonia, or an overall 2,3-amino shift.  The complex architecture of the protein is 
believed to cause formation of the MIO by mechanical compression
6
 and serves to 
position multiple helical dipoles in the active site to allow an enzymatic base to 
deprotonate the benzylic position of aryl amino acids.
7
   
 The investigations of LnmQ and the biosynthesis of leinamycin seeks to also 
answered questions regarding the recognition and activation of non-proteinogenic amino 
acid side chains.  Adenylation domains are able to recognize and activate D-alanine 
specifically over any other amino acid tested.  Recent structural data in a related system 
have shown that bulky residues in the active site can create a small binding pocket with 
only the ability to bind the right stereocenter of alanine.
8
 The synthesis of an aminoacyl 
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adenylate mimic is a promising advance that should aid in the ability to crystallize 
LnmQ.  
 A greater understanding of mechanistic data and recognition events in these 
systems have made it possible to ask new questions.  A selectivity switch was proposed 
that differentiated between activity for phenylalanine and tyrosine in MIO dependent 
lyases, but more studies are needed to determine how all members of the MIO family 
discriminate between aryl amino acids.
9
 It has been shown that simple mutation of His 93 
to a phenylalanine in SgTAM does not cause a change in substrate selectivity 
(unpublished results).  A true understanding of substrate recognition will require more 
mutations in and around the active site of such enzymes.   
 Another lingering question is the lack of a histidine aminomutases (HAM) in the 
known proteome.  Perhaps several exist, or this may be an unresolved mechanism.  If a 
true sense of substrate recognition is gained, current mutases could be modified to favor 
binding histidine over their natural substrates.  
 Discovering how to further relax substrate scope would also greatly benefit the 
field.  Research has already shown that these systems can tolerate some manipulation of 
the aromatic side chain,
4
 but a continued relaxation of binding could allow for the 
chemoenzymatic synthesis of both  and  amino acids as well as ,-unsaturated acids.  
Having access to these scaffolds would help to reduce the cost of these building blocks 
for organic chemistry.    
 One large question that still remains in the field is how are MIO dependent lyases 
and mutases different?  By looking at X-ray crystal structures, differences in a static 
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picture can be scrutinized, but it is still not fully understood why mutases are able to 
catalyze additional chemistry.  If these systems can be changed from mutase to lyase or 
vice versa, a greater understanding of reactivity and mechanism would be obtained.   
 One final experiment that could be done is to change the MIO chromophore to 
that of GFP.  While they are alike in respect to their chromophores, the protein 
environments are so different that it could yield some new insights into the reactivity of 
both prosthetic groups and the role of protein secondary structure.
10
 
 With continued insight into the activation of amino acid building blocks by 
adenylation domains, more information is available for the future engineering of 
adenylation domains to accept different substrates.  Experiments have been done to 
simply replace one adenylation domain with another, but recent data has shown that 
protein/protein interactions are important in these systems,
11
 which would make active 
site manipulation a better avenue for changing a biosynthetic pathway.  
 With the solution of the crystal structure of LnmQ and subsequent engineering of 
the active site, the introduction of different amino acids into the leinamycin structure 
should be done.  Leinamycin has shown very interesting biological activity and would be 
an interesting scaffold with which to experiment.  
 Every result produces more questions than answers and this should make for an 
exciting time in the field of mechanistic enzymology during the next decade.  
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